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GENOMIC AND TRANSCRIPTOMIC LANDSCAPE OF COLORECTAL 
PREMALIGNANCY 
Kyle Chang, B.S. 
Advisory Professor: Eduardo Vilar, M.D., Ph.D. 
Abstract 
Colorectal cancer (CRC) is the third most commonly diagnosed cancer among 
men and women in the United States, with 3 to 5 percent of the cases diagnosed in 
the background of a hereditary form of the disease. Biologically, CRC is divided into 
two groups: microsatellite instable (MSI) and chromosomally unstable (CIN). 
Genomic and transcriptomic characterization of CRC has emerged from large -scale 
studies in recent years due to the advancement of next -generation sequencing 
technologies. These studies have identified key genes and pathways altered in CRC 
and provided insights to the discovery of therapeutic targets. Despite the wealth of 
knowledge acquired in the carcinoma stage, there have been insufficient efforts to 
systematically characterize premalignant lesions at the molecular level, which could 
lead to a better understanding of neoplastic initiation, risk prediction, and the 
development of targeted chemoprevention strategies. The challenge in 
characterizing premalignancy has always been the limited availability of sample 
material. This challenge is tackled by getting more samples, integrating public 
datasets, deploying better technology that use less amount of nucleic acids and in -
silico tools to extract multi-layer information from the same experiment.  
My genomic study consisted of whole exome sequencing (WES) and high-
depth targeted sequencing on 80 premalignant lesions bulk tissue and crypts to 
assess clonality and mutational heterogeneity. WES results showed the presence of 
multiple clone in premalignancy based on clustering somatic mutation allele 
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frequency. In addition, I determined that multiple clones originate from independent 
crypts harboring distinct APC and KRAS alterations. In my second study, I performed 
immune expression profiling and assessment of mutation and neoantigen rate of 28 
premalignant lesions with DNA mismatch repair (MMR) deficient and proficient 
background using RNAseq. My results showed an activated immune profile despite 
low mutational and neoantigen rate, which challenges the canonical view in MMR-
deficient carcinoma stage that immune activation is largely due to high mutation and 
neoantigen rate. In the last study, I performed transcriptomic sub-classifications of 
398 premalignant lesions that associate them with different carc inomas subtypes, 
and clinical and histopathological features. My results revealed two major findings: 
prominent immune activation and WNT and MYC activation in premalignancy.  
In summary, my large-scale genomic and transcriptomic analyses of colorectal 
adenomas have identified key molecular characteristics in early colorectal 
tumorigenesis and provide a foundation for discovering novel preventive strategies . 
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1 INTRODUCTION
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1.1 Colorectal Cancer 
Colorectal cancer (CRC) is the third most commonly diagnosed cancer among men and 
women in the United States[1]. The lifetime incidence of CRC among individuals with average 
risk is 5%. However, individuals diagnosed with hereditary CRC syndromes face significantly 
higher risk at developing CRC at a young age. In fact, hereditary CRC syndromes account for 
35 percent of young adult cancers[2]. There are two main focus of hereditary CRC syndromes: 
Familial Adenomatous Polyposis Syndrome (FAP) and Lynch Syndrome (LS), which account 
for 5% of the total of CRC cases. Both syndromes have an autosomal dominant inheritance 
and predispose individuals to develop colorectal polyps, premalignant lesions to CRC. 
However, FAP and LS exhibit different molecular pathway alterations and phenotype during 
carcinogenesis[3].  
1.2 Familial Adenomatous Polyposis (FAP) 
FAP is characterized by germline mutations in the adenomatous polyposis coli (APC) 
gene, a tumor suppressor[3]. FAP predisposes patients to develop hundreds of adenomatous 
polyps (adenomas) along the gastrointestinal tract and results in 100% lifetime risk of 
developing CRC if left untreated, with majority of diagnoses before the age of 35[3, 4]. The 
majority of the germline mutations are frame-shift or nonsense mutations that lead to premature 
truncation of protein synthesis and the rest manifest as loss of 5q[3]. The germline mutations 
are mostly distributed in the 5’ half of the gene, with two hot spots at codon 1061 and 1309 of 
the β-catenin-binding sites. Germline inactivation of one APC allele greatly increases the rate of 
adenoma formation. It has been observed that FAP patients also acquire somatic APC 
alterations (loss of 5q or mutations), with the majority of the mutations located in the mutation 
cluster region between codon 1309 and 1450. As a result, biallelic loss of APC is a prominent 
feature in premalignant lesions and carcinomas of FAP patients, as well as 80% of sporadic 
CRC patients[3]. APC acts as a binding partner and regulator of β-catenin in the Wnt signaling 
pathway. Then, it leads to phosphorylation and subsequent degradation of β-catenin[3]. 
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However, the loss of APC allows free β-catenin to translocate to the nucleus and activate 
downstream Wnt target genes, which include proto-oncogenes (such as c-MYC and CCND1), 
growth factors (such as FGF20 and FGF9[3]), and continuous renewal of colonic crypts. This 
shows that APC plays a key role in adenoma initiation and growth promotion. Additional 
somatic mutations in key oncogenes and tumor suppressor genes such as KRAS, BRAF, 
SMAD4, TP53 are somatically acquired and chromosomal instability develops during adenoma 
to carcinoma transformation. This process is called the “adenoma to carcinoma” transition 
model[5]. Therefore, FAP has been study widely as a model to understand CRC. 
1.3 Lynch Syndrome (LS) 
LS is caused by germline mutations in one of the DNA mismatch repair (MMR) genes: 
mutL homolog 1 (MLH1), mutS homolog 2 (MSH2), mutS homolog 6 (MSH6), PMS1 homolog2 
(PMS2), or deletions in the epithelial cell adhesion molecule gene (EPCAM)[3, 6]. Approximately 
90% of germline mutations are found in MLH1 and MSH2. It is the most common hereditary 
CRC syndrome, which accounts for 3% of total CRC cases. It is estimated 1 in 280 of the 
population is affected by LS, affecting a total of 1.1 million people in the US[7]. LS patients are 
also at risk of developing endometrial, ovarian, and small intestine cancers[8]. MLH1, MSH2 
and EPCAM germline mutation carriers have similar lifetime risks for developing CRC, at 
approximately 70%[8],[9]. Although MSH6 carriers have markedly lower risk in developing CRC 
(~20%), they still have 40% risk of developing LS-associated cancers[8]. Cancer develops in 
LS patients when they acquire a somatic mutation in the alternate allele of the same gene that 
carries the germline mutation. The resulting biallelic inactivation of MMR gene causes a rapid 
accumulation of mutations, particularly insertions and deletions, in microsatellites across the 
genome due to the fact that they are particularly susceptible to DNA polymerase slippage[10]. 
A subset of these mutations inevitably inactivates tumor suppressor genes or activates 
oncogenes, which accelerates the progression from adenoma to carcinoma. This molecular 
phenotype is called microsatellite instability (MSI) and occurs in about 15% of CRC[11, 12]. It is 
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estimated that the transformation only take a few years at most in LS patients, compared to 
decades in average-risk population[3]. Although screening with annual colonoscopy has been 
demonstrated to decrease cancer incidence in LS[13], many patients continue developing CRC 
at a young age due to poor compliance with screening recommendations or the rapid 
development of interval cancers due to not yet well defined biologic reasons[14]. Interestingly, 
MSI carcinomas have relatively good prognosis and lower frequency of distant metastases 
compared to non-MSI carcinomas[12]. 
1.3.1 Microsatellite Instability and Immune Microenvironment 
Carcinomas from LS patients or sporadic cases exhibit microsatellite instability due to 
MMR deficiency. Thus, they accumulate an excessive number of frame-shift mutations, which 
result in high amounts of mutated frameshift peptides (or neoantigens). The neoantigens are 
presented on cancer cells through binding the histocompatibility complex I or II (MHC I, MHC 
II). They are subsequently recognized by the immune system CD8+ cytotoxic T cells for MHC I 
antigens or by CD4+ helper T cells for MHC II antigens. As a consequence, neoantigens will 
activate the host immune response and cause T cell infiltration[15]. Although the activated T 
cells induce destruction tumor cells either by secreting cytotoxic molecules or pro-inflammatory 
cytokines, these neoantigens also upregulate immune inhibitory molecules such as PD-1, PD-
L1, LAG-3 and other checkpoint inhibitors to counterbalance the infiltrating immune T cells[16]. 
As a result, the antitumor immune response is significantly impaired. Additional impairment of 
antitumor immune response includes mutations in genes involved in antigen presentation, such 
as beta2-mciroglobulin (B2M), and antigen regulators such as Class II Major Histocompatibility 
Complex Transactivator (CIITA) or Regulatory Factor X5 (RFX5) have been identified in MSI 
CRC which impair antigen expression to T cells[17]. Therefore, restoring antitumor immune 
response has the potential to eliminate MSI carcinomas. In fact, treatment of MSI carcinomas 
with the checkpoint inhibitor Pembrolizumab or Nivolumab has been shown to recover 
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antitumor function of T cells and demonstrated clinical benefit in terms of prolongation of 
progression free and overall survival[18-20].  
1.4 Serrated Pathway 
An alternative route of colorectal carcinogenesis is the serrated pathway and potentially 
accounts for up to one third of all CRC[3, 21]. This pathway is associated with high CpG island 
methylation phenotype (CIMPhi) and BRAFV600E mutations as the major driving mechanisms in 
both sporadic and familial cases[22] [23]. The serrated pathway has been linked to serrated 
polyps, which are different from traditional adenomas due to the “saw-toothed” appearance. 
This group of polyps are divided into hyperplastic polyps (HP), traditional serrated adenomas 
(TSA), and sessile serrated adenomas (SSA). HP is the most common type of polyp and is 
typically found in rectosigmoid colon. Although HP is considered as non-neoplastic, there is 
some evidence that it can progress into SSA, which has higher risk of developing into CRC[21, 
22]. While SSA is more commonly found in proximal colon, TSA is more commonly found in 
rectosigmoid colon. Due to the malignant potential of TSA/SSA, they are both managed like 
traditional adenomas in the clinic[21, 22]. Serrated/hyperplastic polyposis syndrome (SPS) is a 
condition characterized by multiple and/or large HP or TSA/SSA in the colon. Approximately 
33-59% of the individuals diagnosed with SPS have a family history of CRC but no germline 
mutation has been identified[21]. 
1.5 Clonality in Premalignancy 
Intestinal epithelium undergoes continuous renewal of epithelial cells in crypts[24]. This 
process is maintained by stem cells at the base of crypts. The colorectal carcinogenesis model 
assumes that a single stem cell in a crypt (founder clone) acquires an APC alteration and 
accelerates mutated crypt expansion in a process called crypt fission[24, 25]. Therefore, 
neoplastic initiation is described as “monocryptal” in origin[24]. The founder clone, driven by the 
APC alteration, grows into a dominant population or clone. Consequently, APC alteration 
becomes a truncal or clonal event present in the majority of CRC. Subsequent acquisition of 
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alterations, such as KRAS mutations, provide additional growth advantage and drive further 
tumor progression. KRAS mutations are present in a restricted, although significant, proportion 
of dysplastic cells, and generate subclones with different mutations that contribute to another 
level of intra-tumoral heterogeneity (ITH) early in carcinogenesis.  
Advancement in next-generation sequencing and bioinformatics tools allow 
investigating such heterogeneity at high resolution. Computation tools such as ABSOLUTE and 
EXPANDS provides estimation on clonal composition based on somatic mutations generated 
from bulk tissue sequencing[26, 27]. These methods estimate the fraction of cancer cells 
containing a mutation by integrating mutation allele frequency, copy number variation, and 
tumor purity. For example, if all cancer cells contain a heterozygous mutation (clonal mutation) 
in a copy neutral region, then half of the reads are expected to support the mutation (0.5 allele 
frequency). Alternatively, if only half the cancer cells contain a heterozygous mutation 
(subclonal mutation) in a copy neutral region, then only 25 percent of the reads are expected to 
support the mutation (0.25 allele frequency). Therefore, clustering of the mutations’ allele 
frequency, in a background of ploidy and purity, allows inference on the number of tumor 
clones.  
1.6 The Consensus Molecular Subtypes of Colorectal Cancers 
The canonical genetic pathways underlying the malignant transformation of colonic 
mucosa have been well characterized by Vogelstein et al[3, 5]. Specifically, they described a 
step-wise cascade of somatic mutations in tumor suppressor genes (e.g. APC, TP53, SMAD4) 
and oncogenes (e.g. KRAS, PIK3CA) and additional epigenetic aberrations that are now 
strongly implicated in colorectal cancer (CRC) initiation and growth[11]. For example, at the 
structural level, it has been shown that chromosomal instability (CIN) in the context of these 
driver mutations helps to promote tumor invasion. Indeed, imbalances in chromosome number 
(aneuploidy) and loss-of-heterozygosity are seen in 85% of invasive CRC tumors[28]. However, 
CRC is a heterogeneous disease with diverse biological characteristics that influence a 
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patient’s treatment options and prognosis that cannot simply be characterized by genetic and 
epigenetic alterations. Therefore, additional layers of molecular data by gene expression 
profiling, linked with genetic, epigenetic and clinical features, have been performed extensively 
to identify biological subtypes of CRC to provide a robust molecular characterization of CRC 
and a basis for clinical and translational stratification[29-33]. Despite various efforts in subtype 
identification, there have been a lack of consensus results due to different data platforms, 
processing methods, and algorithm designs implemented in these studies and impeded 
adoption in clinical and translational settings[29-32]. To reduce the discrepancies seen in 
different subtype identification strategies, Guinney et al provided a general framework by 
integrating various subtyping strategies[34]. They performed network analyses to study the 
associations of subtype labels used in different subtype classification system and identified four 
groups of subtype labels with significant associations which were termed “Consensus 
Molecular Subtypes” (CMSs). Using CMS labels as the gold standard, they developed a novel 
CMS prediction model using a random forest classifier on different gene expression platforms 
(Illumina RNAseq, Affymetrix and Ailgent arrays) and sample types (FFPE, fresh-frozen). 
Furthermore, CMS groups were associated with key genomic and epigenomic markers, clinical 
and pathological features, and prognosis[34]. In summary, each CMS group displays the 
following distinguished biological features: (1) CMS1, characterized by hypermutation, MSI, 
enrichment for BRAFV600E mutation, and strong immune activation; (2) CMS2, a “canonical” 
subtype with marked WNT and MYC signaling activation and EGFR dependence; (3) CMS3, 
enriched for KRAS mutations and evident metabolic dysregulation; and (4) CMS4, a 
mesenchymal subtype, with prominent TGFβ activation, an immunosuppressive 
microenvironment, stromal invasion and angiogenesis activation. Notably, CMS tumor 
classification was shown to stratify CRC patients into distinct prognostic subgroups[34] and 
provide valuable insights for managing both early-stage and advanced disease. 
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1.7 Dissertation Objective 
Genomic and transcriptomic characterization of CRC has emerged from large-scale 
studies in recent years due to the advancement of next-generation sequencing 
technologies[11, 34]. These studies have identified key genes and pathways altered in CRC 
and provided insights to the discovery and development of therapeutic targets[35, 36]. Despite 
our knowledge of the carcinoma stage, we have not fully explored the molecular characteristics 
of colorectal premalignancy, which can improve our understanding of neoplastic initiation and 
development of chemoprevention strategies. Therefore, there is an urgent need to establish a 
comprehensive molecular annotation of the biological pathways and a multi-layer model of 
initiation in colorectal premalignancy. 
My long-term goal is to improve and develop novel CRC chemoprevention strategies by 
inhibiting initiation of premalignant lesions and their transformation into carcinomas, as well as 
risk prediction of individuals with premalignancy. The objective of this dissertation is to 
establish a model of initiation, characterize the immune expression profile and its relation to 
mutation and neoantigen load in MMR-deficient carcinogenesis, and analyze the sub-
classification of premalignancy in association with different CRC subtypes to provide a 
comprehensive molecular characterization of colorectal premalignancy. My central hypothesis 
is that such large-scale genomic and transcriptomic characterization effort of premalignant 
lesions using next-generation sequencing technologies can provide insights into the molecular 
mechanisms of early colorectal tumorigenesis. The basis of this dissertation is derived from (i) 
the monocryptal polyclonal model of initiation in CRC carcinogenesis, (ii) the dependency of 
immune activation on high mutation rate and neoantigen load in MMR-deficient CRC, (iii) the 
established molecular classification of CRC using transcriptomic-based subgroups with 
prognostic and therapeutic features associated. Therefore, I will test the central hypothesis with 
the following specific aims:  
1. To assess the presence and the origin of clonality in premalignancy.  
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1.1. To determine the presence of clonality in premalignancy. My working hypothesis is that 
estimating the fraction of cells containing somatic mutations and clustering their 
frequencies will allow inferring the number of tumor clones. I will use the bioinformatics 
tool ABSOLUTE to estimate tumor clones of premalignant lesions using data derived 
from whole exome sequencing.  
1.2. To assess the origin of clonality in premalignancy. My working hypothesis is that there 
are independent clones derived from independent crypts (polyclonal polycryptal model) 
versus independent clones initiated from one ancestral crypt (polyclonal monocryptal 
model). I will detect distinct initiating APC and driver KRAS alterations in tissue 
biopsies and crypts using high-depth targeted sequencing and digital array 
technologies.  
2. To determine the temporal changes in the immune expression profile and its relation to 
mutation and neoantigen rates from MMR-deficient premalignancy to carcinoma stages. My 
working hypothesis is that mutation and neoantigen rate arise late in the MMR-deficient 
carcinogenesis and are independent of the immune expression profile displayed in LS 
premalignancy. I will measure the expression of genes linked to the immune 
microenvironment (Th1/Tc1, CTL, Th17, Treg, proinflammation, and metabolism) and 
calculate mutation and neoantigen rates using whole transcriptome sequencing. 
3. To determine the transcriptomic sub-classifications of premalignant lesions that associate 
them with different carcinomas subtypes, clinical and histopathological features. My working 
hypothesis is that the analysis of the transcriptomic profiles of premalignant lesions in the 
context of carcinomas subtypes can define specific events driving initial steps of 
carcinogenesis. I will apply CRC subtype classifier on the transcriptome data of 
premalignant lesions generated from microarray and whole transcriptome sequencing. 
The research design and above specific aims are presented in the following chapters. In 
chapter 2, I present the research design and methods used in all the chapters of this 
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dissertation. In chapter 3, I present the results of the project on the origin of clonality in 
premalignancy. In chapter 4, I present the results of the project studying the immune 
expression, mutation and neoantigen rates. Lastly, in chapter 5, I present the results of the 
project studying the transcriptomic sub-classification and pathway enrichments in 
premalignancy. 
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2 MATERIALS AND METHODS
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Chapter 2 MATERIALS AND METHODS 
The content of this chapter is based on the following publications: 
Gausachs M, Borras E, Chang K, Gonzalez S, Azuara D, Delgado Amador A, Lopez-Doriga A, 
San Lucas FA, Sanjuan X, Paules MJ, Taggart MW, Davies GE, Ehli EA, Fowler J, Moreno V, 
Pineda M, You YN, Lynch PM, Lazaro C, Navin NE, Scheet PA, Hawk ET, Capella G, Vilar E. 
Mutational Heterogeneity in APC and KRAS Arises at the Crypt Level and Leads to 
Polyclonality in Early Colorectal Tumorigenesis. Clin Cancer Res. 2017 Oct 1;23(19):5936-
5947. doi: 10.1158/1078-0432.CCR-17-0821. Epub 2017 Jun 23. PubMed PMID: 28645942; 
PubMed Central PMCID: PMC5626604. 
 
Borras E, San Lucas FA, Chang K, Zhou R, Masand G, Fowler J, Mork ME, You YN, Taggart 
MW, McAllister F, Jones DA, Davies GE, Edelmann W, Ehli EA, Lynch PM, Hawk ET, Capella 
G, Scheet P, Vilar E. Genomic Landscape of Colorectal Mucosa and Adenomas. Cancer Prev 
Res (Phila). 2016 Jun;9(6):417-27. doi: 10.1158/1940-6207.CAPR-16-0081. Epub 2016 May 
24. PubMed PMID: 27221540; PubMed Central PMCID: PMC4941624. 
Copyright permissions are not required, since AACR states “Authors of articles published in 
AACR journals are permitted to use their article or parts of their article in the following ways 
without requesting permission from the AACR - Submit a copy of the article to a doctoral 
candidate's university in support of a doctoral thesis or dissertation.” 
 
Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San 
Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz 
S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E. Immune Profiling of Premalignant 
Lesions in Patients with Lynch Syndrome. JAMA Oncol. 2018 Apr 16. doi: 
10.1001/jamaoncol.2018.1482. 
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Copyright 2018 by JAMA Oncol. Reproduced with permissions of JAMA Oncol via Copyright 
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2.1 Genomic Profiling 
2.1.1 Patients and Samples 
A total of 80 colorectal adenomas from individuals with hereditary cancer syndromes and 6 
tumors from sporadic cases were at collected at either the Catalan institute of Oncology or The 
University of Texas MD Anderson Cancer Center (UTMDACC). 25 of the total adenomas were 
analyzed with whole exome sequencing (Table 1), 37 of the total adenomas were analyzed 
with high-depth Ampliseq targeted sequencing and SNP arrays, and 18 of the total adenomas 
and 6 tumors were sectioned into multiple bulk biopsies and crypts and analyzed with digital 
genotyping technology (Table 2). 
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Table 1. Clinical characteristics of patients analyzed with WES 
Patient 
ID 
Gender Age Race 
Pr 
Sx 
No. of 
polyps 
detected 
Cancer 
Dx 
APC germline 
No. Adenomas 
analyzed  
CATA01 F 28 W P NA 
  
c.3927_3931delAAAGA  4 
CATA02 F 22 W IRA NA D c.4393_4394delAG 3 
CATA03 M 38 W P >100 
  
c. [1958+3G>A(;)c.1959G>A] 1 
CATA04 M 47 W P NA CC c.1412delG 4 
MDAC01 M 35 W IRA >100 
  
c.1880dupA 2 
MDAC02 M 33 W IRA <5 
  
c.3810T>A 1 
MDAC03 F 63 AA IRA <50 
  
del exons 11-12 - 
MDAC08 M 42 W P >100 
HCC, 
D 
c.622C>T 2 
MDAC10 F 22 W P <5 HepBl c.3440dupA 1 
MDAC14 F 40 W* IRA <5 
  
del 8-9 3 
MDAC17 M 37 W IRA <5 
  
c.1658G>A 2 
MDAC18 M 27 W P >100 D c.4393_4394delAG 1 
MDAC20 M 65 W IRA <50 
  
c.477C>G 1 
MDAC21 F 70 W IRA <5 
  
c.487C>T - 
MDAC24 F 25 AA NP >100 D c.4733_4734del - 
MDAC26 F 28 W IRA >100 
EC, 
OC 
c.847C>T - 
MDAC29 F 25 W P >100 
  
c.3810T>A - 
MDAC32 F 58 AA NP <50 
  
c.1620insA - 
MDAC33 M 43 W NP >100 
  
c.2894delA - 
MDAC34 M 29 W NP <50 
  
c.5936delA - 
Abbreviations: Pr Sx, Prophylactic Surgery; M, male; F, Female; W, white; AA, african-american; IRA, Ileorectal anastomosis; P, 
Pouch; NP, not performed; HCC, Hepatocellular carcinoma; HepBI, Hepatoblastoma; D, Desmoid; EC, Endometrial cancer; OC, 
Ovarian cancer. 
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Table 2. Clinical characteristics of patients analyzed with Ampliseq, SNP arrays, and 
digital genotyping. 
Patient     Germline 
information 
Adenomas 
Tumor 
characteristics 
      
Patient Gender Age Gene Location Grade Size 
(cm) 
Stage 
FAP1 M 19 APC >150 - - - - 
MAP1 F 46 MUTYH 80-90 - - - - 
UFP1 M 54 APC and 
MUTYH 
30-40 - - - - 
UFP2 M 48 APC and 
MUTYH 
120 - - - - 
LYN1 F 51 MLH1 - left high 5.5 pT2 N0 mx/R0 
CMMRD1 F 44 PMS2 - - - - - 
SP1 F 67 - - left low 3.5 pT3ab N1 
SP2 M 73 - - right low 5 pT3ab N2 Mx/R0 
SP3 M 72 - - right high 6 pT3cd (2) N0 
Mx/R0 
SP4 F 83 - - right low 6 pT2 N0 Mx/R0 
SP5 M 75 - - right high 9.5 pT2 N0 Mx/R0 
SP6 M 75 - - right low 6.5 pT3 N0 Mx/R0 
MDAC02 M 33 APC <5 - - - - 
MDAC03 F 63 APC <50 - - - - 
MDAC10 F 22 APC <5 - - - - 
MDAC14 F 40 APC <5 - - - - 
MDAC17 M 37 APC <5 - - - - 
MDAC18 M 27 APC >100 - - - - 
MDAC20 M 65 APC <50 - - - - 
MDAC21 F 70 APC <5 - - - - 
MDAC24 F 25 APC >100 - - - - 
MDAC26 F 28 APC >100 - - - - 
MDAC29 F 25 APC >100 - - - - 
MDAC32 F 58 APC <50 - - - - 
MDAC33 M 43 APC >100 - - - - 
MDAC34 M 29 APC <50 - - - - 
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Whole Exome Sequencing 
A total of 25 colorectal adenomas and matched blood samples from 12 patients 
diagnosed with FAP at the Catalan Institute of Oncology and UTMDACC at the time of 
endoscopic surveillance and were either fully resected or biopsied with snare forceps (Table 1). 
Tissues were retrieved from the endoscopy suite or the operating room and immediately flash-
frozen or preserved in RNAlater storage solution (Life Technologies) and then stored at –80°C 
according to internal protocols. Blood was collected in EDTA tubes and stored appropriately for 
subsequent extraction of germline DNA. Genomic DNA was extracted from whole blood using 
the Blood & Cell Culture DNA Mini Kit (Qiagen) and from tissues using the QIAmp DNA Mini Kit 
(Qiagen). Exome DNA was captured using the SeqCap EZ Human Exome library v3.0 capture 
chip (Roche NimbleGen), which has a target capture region of 64 Mb. Samples were 
sequenced on an Illumina HiSeq 2000 sequencer with 76-base paired-end reads at the MD 
Anderson Sequencing Core Facility. Reads were aligned with the Burrows-Wheeler Alignment 
(BWA)[37] software to reference human genome version hg19. The initial alignment results 
were further processed with local realignment, duplicate read marking, and base quality 
recalibration by using Picard and the Genome Analysis Toolkit (GATK)[38] and by applying 
recommended best practices for sequence analysis from the Broad Institute. 
2.1.2 Mutation Detection in WES 
We used MuTect 1.14[39] for calling point mutations and Indelocator[40] for calling 
small 
insertions and deletions. Somatic events called by MuTect and Indelocator were annotated with 
Annovar[41] and Variant Tools[42] with population allele frequencies of the 1000 Genomes 
Project and the Exome Variant Server (data release version ESP6500) for subsequent filtering 
of likely common polymorphisms and false positives. We excluded candidate somatic 
mutations seen at 1% or greater population allele frequency in either of these projects. All point 
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mutations, small insertions, and deletions were visually verified using the Integrated Genome 
Viewer[43].  
2.1.3 Mutational Signature Analysis  
Mutation signatures were detected and plotted with deconstructSigs_1.8.0[44] 
2.1.4 Allelic Imbalance Analysis 
HapLOH[45] was used to detect allelic imbalance in SNP array. It combines the 
haplotype estimate, the SNP array’s B allele frequencies (BAFs), and log R ratios (LRRs) to 
detect the deviations of phase concordance expected in blood samples. Then, a hidden Markov 
model (HMM) was applied to identify regions of subtle AIs. The over-represented alleles were 
called to classify AI regions into amplifications, deletions, cn-LOH, or indeterminable AI. 
HapLOHSeq[46], an extension to hapLOH, was used to detect allelic imbalance in whole 
exome sequencing and RNA sequencing data. To classify allelic imbalance (AI) events as 
amplification, deletion, or copy neutral LOH (cn-LOH), we used a hypothesis testing framework, 
with a null hypothesis of no presence of copy number changes between the blood and the 
adenoma samples in the region of AI (thus, cn-LOH) and an alternative that there are changes 
(deletion or amplification). We first applied a coverage normalization factor, for each 
adenoma/blood pair, across the exome to harmonize total coverage between the paired 
samples. Next, we calculated the mean coverage difference between the paired samples within 
each AI region. To establish significance of the putative deletion or amplification, we then 
applied a permutation-based test as follows: for each event, 10,000 permutations were 
performed, in which we randomly assigned sample labels at each genomic site and calculated 
a mean coverage difference between the adenoma and blood. The mean coverage difference 
obtained using the true sample labels was then compared with those generated from the 
permuted labels, and a permutation P-value was calculated as the frequency of permuted 
coverage differences that had a more extreme value than the true value. The null hypothesis of 
cn-LOH was rejected for permutation P-values ≤0.05. In such cases, the copy number 
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alteration was determined to be the putative call (depending on the direction of coverage 
differential). 
2.1.5 Clonality Estimation with WES 
Somatic point mutations detected by MuTect 1.14[39] using default settings were 
filtered for “PASS” mutations. Copy number variations were detected using VarScan 2.3.7[47] 
with P = .01 and data-ratio=adenoma and matched blood reads ratio. VarScan log2ratio output 
was segmented with DNAcopy[48].We estimated the number of clones in adenomas by 
constructing kernel density estimation (KDE) using mutation cancer cell fractions (CCFs) and 
solving for the number of modes in the KDE. In the analysis of stage I CRC from TCGA, 
ABSOLUTE inputs are somatic point mutations obtained from the TCGA data portal and copy 
number variations obtained from the SNP Array 6.0 calls of the Broad Institute’s Firehose 
portal. 
2.1.6 Ion Torrent Ampliseq Panel Analysis 
A total of 37 adenoma samples from FAP patients with an IT Personal Genome 
Machine (PGM; Life Technologies) by the Sequencing and Non-Coding RNA Program at MD 
Anderson using the Ion PGM 200 Sequencing Kit on an Ion 318 Chip Kit (Life Technologies) 
(Table 2). IT Variant Caller v4.2 was run in the somatic low stringency mode to detect variants 
in APC and KRAS against reference human genome version hg19 on each adenoma and 
matched normal samples. Then, normal variants were subtracted from matched adenoma 
variants to create a list of somatic candidates for each adenoma and normal pair. Events 
located within the first and last 15% of the bases of the read were excluded. Then, a list of 
somatic candidates went through the following quality control steps: 1) Mutation allele 
frequencies were re-evaluated after removing variant reads where the mutation lies within the 
first 15% or last 15% of the bases of the reads; 2) Mutations with more than 2 variant alleles 
were excluded; 3) Mutations must be covered by a minimum of 100 reads. If a mutation allele 
frequency is 2-5% at least 10 reads must show the variant allele. If a mutation allele frequency 
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> 5% at least 25 reads must show the variant allele. Validation of somatic mutations and indels 
were performed using Sanger sequencing. 
2.1.7 SNP Arrays 
SNP arrays from 37 FAP adenoma samples (Table 2) were performed using the 
HumanOmniExpressExome beadChip array (Illumina, San Diego, CA). This array contains 
964,193 markers including 273,246 markers specific to the exome. The DNA input for each 
sample was 200 ng. Intensity files (.idat) were used to make genotyping calls in GenomeStudio 
software utilizing the Illumina-supplied cluster file.  
2.1.8 Colony genotyping assay and power calculation 
We performed a colony genotyping assay to determine whether the two APC 
somatic mutations [Somatic #1 (S1) and Somatic #2 (S2)] detected in one of the 
adenomas belonged to different alleles and therefore to independent clones or if they 
could be present in the same allele. We performed a long-range PCR (LR-PCR) in the 
adenoma sample using LaTaq polymerase (TaKaRa Bio Inc, Shiga, Japan). Then, the 
PCR product was purified from the gel using the QIAquick gel extraction kit (Qiagen), 
ligated to the plasmid pGEM-Teasy Vector System II with T4 DNA ligase (Promega, 
Madison, WI) and genotyped using one Taqman assay per mutation (AHN1X23, 
AHPAV65 and AHZAHK3, Applied Biosystems, Maryland, USA). All samples were 
genotyped by triplicate and positive and negative controls for all mutations were 
included in every single plate. Controls were colonies that were validated previously 
using Sanger Sequencing. We performed a power calculation to determine the 
minimum number of assays (n) required to observe Somatic #1 and Somatic #2 
separately at least 3 times with 95% power and determined that at least 82 clones were 
needed. The estimation of the tumor purity in our adenoma was consistent with 30% of 
dysplastic cells and 70% of normal cells[49]. Our Ampliseq sequencing results observed 
that S1 and S2 have similar allelic frequencies. Based on these premises, the 
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probability of observing a heterozygous S1 (Pr(s1)) and a heterozygous S2 (Pr(S2)) are 0.075. 
Thus, we can define our power calculation as the following: Probability of observing S1 >2 
times and S2 >2 times in n assays. 
= Pr(𝑆1 > 2 𝑎𝑛𝑑 𝑠2 > 2) 
= ∑ Pr( 𝑆1 > 2 𝑎𝑛𝑑 𝑆2 > 𝑖)
𝑛
𝑖=2
 
= ∑ Pr(𝑆1 > 2|𝑆2 = 𝑖) Pr(𝑆2 = 𝑖)
𝑛
𝑖=2
 
= ∑[1 − Pr(𝑆1 = 0|𝑆2 = 𝑖) − Pr(𝑆1 = 1|𝑆2 = 𝑖) − Pr (𝑆2 = 2|𝑆2 = 𝑖)]
𝑛
𝑖=2
Pr (S2 = i) 
= ∑ [1 − (1 − Pr(S1))𝑛−𝑖 − (
𝑛 − 𝑖
1
) Pr(𝑆1)1 (1 − Pr(S1))𝑛−1−𝑖
𝑛
𝑖=2
− (
𝑛 − 𝑖
2
) Pr(𝑆1)2 (1 − Pr(S1))𝑛−2−𝑖] Pr(S2 = i)  
 
2.1.9 Crypt isolation  
A total of 18 adenomas and 6 tumors were minced into 3 mm pieces, incubated in 
30mM EDTA in HBSS for 20 min, and vigorously shaken to obtain a supernatant enriched for 
crypts (Table 3). The same day of the sample collection individual crypts were picked up under 
microscope and were placed into 0.5 mL microfuge tubes. Normal crypts were easily 
distinguishable from tumor crypts based on their characteristics (normal crypts were small and 
nonbranched, while tumor crypts were large and displayed sheets of epithelium with thick 
clusters of different sizes)[50]. This method limits the contamination of non-neoplastic cells by 
an efficient separation of lamina propria mucosa or stroma[51]. Isolation of individual crypts 
was verified by microscopy in a selection of cases to ensure that the molecular analysis was 
representative of individual crypts and that the methodology for isolation was consistent. 
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Table 3 Number of adenomas, bulk biopsies and crypts isolated for APC and KRAS 
mutation analysis. 
Patient ID 
# 
Sample 
# Bulk  
Biopsies 
# 
Crypts 
# 
Sample 
# Bulk  
Biopsies 
# 
Crypts 
CMMRD1 1 1 10 0 0 0 
FAP1 3 8 30 0 0 0 
LYN1 0 0 0 1 1 10 
MAP1 3 2 30 0 0 0 
SP1 0 0 0 1 4 10 
SP2 0 0 0 1 6 10 
SP3 0 0 0 1 6 10 
SP4 0 0 0 1 6 10 
SP5 0 0 0 1 5 10 
SP6 0 0 0 1 5 10 
UFP1 4 5 43 0 0 0 
UFP2 7 10 62 0 0 0 
total 18     6     
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2.1.10 APC mutations in bulk and crypt samples 
A fragment of 1650 base pairs (bp) of the mutational cluster region (MCR) was 
amplified and then sequenced in biopsy sections. For crypt analysis, a nested PCR approach 
was performed to increase the amount of DNA template. All detected alterations were validated 
in at least 3 independent reactions and verified by two independent reviewers. Normal mucosa 
biopsies and normal crypts from the same cases were also analyzed in parallel to rule out 
random acquisition of APC mutations or PCR artifacts. 
2.1.11 KRAS hotspot mutations in bulk and crypt samples 
In bulk biopsies, genotyping of KRAS hotspot mutations was performed using allele-
specific probes for seven KRAS mutational hotspots (G12A, G12C, G12D, G12R, G12S, G12V 
and G13D) in the Digital Array platform (Fluidigm Corporation, South San Francisco, CA; with 
an analytical sensitivity from 0.05% to 0.1%, depending on the mutation analyzed [52]. In 
crypts, the same assays were performed using the 48.48 BioMark Dynamic Array (Fluidigm 
Corporation) after a pre-amplification step. The analytical sensitivity of the Dynamic Array for 
the detection of the mutant allele oscillated between 5-12.5%. In the absence of detectable 
DNA contamination, consistent results were obtained in sixtuplicates allowing for robust 
observations. Median values of replicates were used to quantify the amount of mutant alleles. 
The quantitation of the signal was extrapolated from standard curves generated from 
reconstitution experiments that also allowed the definition of conservative thresholds. 
Of note, we carefully ruled out the introduction of systematic DNA contamination as a 
consequence of performing the pre-amplification of DNA using a nested PCR approach by 
using multiple independent steps. First, mastermix preparation, DNA pipetting, first PCR 
amplification, and second PCR amplification were all performed in four separate rooms, where 
different instrumentation was used. Second, we always kept a unidirectional flow for all the 
samples. Third, controls for contamination were included in every single PCR reaction. 
Contamination controls for the first external KRAS PCR reaction were re-amplified together 
  24 
including always specific positive and wild-type controls. Fourth, random sets of amplicons 
were tested specific KRAS mutation probes using conventional real-time PCR analysis by 
LightCycler 480 to add an additional contamination control, always ruling out the presence of 
contamination. Finally, we performed a total of six replicates for each assay using the 48.48 
Dynamic Array on the BioMark platform (Fluidigm Corporation) in order to re-assure on the 
robustness of our results. 
2.1.12 Metapopulations analysis in crypts 
The percentage of KRAS mutant cells for each crypt was extrapolated from the allele 
frequencies in each crypt. Hierarchical clustering of crypt data was performed to evaluate the 
relationship between metapopulations of crypts in adenomas and carcinomas using Euclidean 
distance for measuring similarity across crypts and complete linkage methods for clustering. 
The grouping of the metapopulations was performed using the “pvclust” package[53], which 
generates probability values using the bootstrap resampling technique. 
2.2 Immune Profiling 
2.2.1 Patients and Samples 
A total of 28 colorectal polyps (26 tubular adenomas and 2 hyperplastic polyps) from 21 
patients diagnosed with FAP (n=21) and LS (n=11) at UTMDACC and 3 early stage colorectal 
tumors (one stage I and two stage II) from 3 patients diagnosed with LS obtained by Nouscom 
SRL from “Regina Elena” National Cancer Institute, Rome, Italy. All of the patients had their 
diagnosis confirmed by genetic testing performed at a Clinical Laboratory Improvement 
Amendments (CLIA) laboratory and carried mutations in APC (n=10), MLH1 (n=3), MSH2 
(n=5), MSH6 (n=5) and PMS2 (n=1) (Table S1). Polyps were collected at the time of 
endoscopic surveillance and were either fully resected or biopsied with snare forceps. Tumors 
were collected at the time of surgical resection. All tissues were immediately flash-frozen or 
preserved in RNAlater storage solution (Life Technologies, Carlsbad, CA) and then stored at –
80°C according to internal protocols. Total RNA was extracted using TRIzol (Invitrogen, 
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Waltham, MA) and the RNeasy kit (Qiagen). RNA was quantified using Qubit 
(LifeTechnologies) and RNA quality with the Agilent 2100 Bioanalyzer in order to select 
samples for analysis based on RNA integrity numbers for analysis. The diagnosis of 
adenomatous versus hyperplastic polyps and tumors was confirmed by an expert 
gastrointestinal pathologist in all samples that rendered enough tissue for both nucleic acid 
extraction and pathologic confirmation (Table 4, and Supplementary Table S2Error! Reference 
source not found. in Chang, Kyle, et al. "Immune Profiling of Premalignant Lesions in Patients 
With Lynch Syndrome." JAMA oncology (2018)). Informed consent was obtained from all 
individuals, and the IRB approved this study (UTMDACC Protocol ID number: PA12-0327). In 
addition, a total of 47 CRC (6 hyper-mutants and 41 non-hypermutants) were downloaded from 
The Genomics Data Commons13 for comparative analysis with carcinomas.  
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Table 4. Clinical characteristics of FAP and LS patients 
Patient 
ID 
Gende
r 
Ag
e 
Rac
e 
Colorecta
l Sx 
No. of 
polyps 
detecte
d 
Cancer 
Dx 
Germlin
e 
mutatio
n 
No. of 
normal 
mucosa  
sequence
d 
No. of 
adenomas 
sequence
d 
No. of 
tumors 
sequence
d 
Gene 
FAP_1 M 35 W IRA >100   APC 1 2 0 
FAP_2 M 33 W IRA <5   APC 1 2 0 
FAP_3 F 42 W IRA 5   APC 1 2 0 
FAP_4 M 42 W P >100 HCC, D APC 1 3 0 
FAP_5 F 40 W IRA 5   APC 1 1 0 
FAP_6 M 37 W IRA <5   APC 1 1 0 
FAP_7 M 65 W IRA <50   APC 1 1 0 
FAP_8 F 25 AA NP >100 D APC 1 2 0 
FAP_9 F 28 W IRA >100 EC, OC APC 1 1 0 
FAP_1
0 
F 25 W P >100   APC 1 1 0 
LS_1 M 53 W RH 1 CC MSH6 1 1 0 
LS_2 F 46 W NP 3 EC MSH2 1 1 0 
LS_3 M 52 W LH 1 CC PMS2 1 1 0 
LS_4 F 37 W NP 1   MSH2 1 1 0 
LS_5 F 53 W NP 1   MSH2 1 1 0 
LS_6 M 58 W NP 2   MSH2 1 1 0 
LS_7 M 76 W LH 2 CC MSH2 1 1 0 
LS_8 F 68 W NP 4 EC MSH6 2 1 0 
LS_9 F 62 W NP 1 EC MSH6 1 1 0 
LS_10 F 43 W RH 3 CC MSH6 1 1 0 
LS_11 F 63 W TCR 3 CC, EC MSH6 1 1 0 
LS_12 F 35 W SC 0 CC MLH1 1 0 1 
LS_13 F 76 W SC 0 CC, BC, 
GIST 
MLH1 1 0 1 
LS_14 F 61 W RH 0 CC PMS2 1 0 1 
Abbreviations: M, male; F, Female; W, white; AA, African-American; IRA, ileorectal anastomosis; P, pouch; RH, right 
hemicolectomy; LH, left hemicolectomy; TCR, transverse colon resection; SC, subtotal colectomy; NP, not performed; NA, not 
available; CC, colon cancer; HCC, hepatocellular carcinoma; HepBI, hepatoblastoma; D, desmoid; EC, endometrial cancer; OC, 
ovarian cancer.  *Denotes Hispanic ancestry. 
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2.2.2 RNA Sequencing 
 Sample preparation, library construction, and sequencing were performed at 
UTMDACC Sequencing Core Facility and the Center for Genomics and Transcriptomics 
(Tuebingen, Germany). For polyps, transcriptome analysis was performed with the Illumina 
HiSeq 2000 instrument generating paired-end 75-base pair (bp) reads when 8 samples are 
multiplexed using barcodes. Each sample had an average of 40 million read pairs and an 
average alignment rate of 84.83% (SD=2.98%). For tumors, transcriptome analysis was 
performed with the Illumina HiSeq 4000 instrument generating paired-end 100-bp reads. Each 
sample had an average of 27.5 million read pairs and an average alignment rate of 76% 
(SD=0.04%).  Reads were mapped to human genome assembly b37 using STAR 
v2.5.1b_modified in 2-PASS mode. During STAR first-pass, reads are aligned against 
transcript definition from gencode.v19. Splice junctions output during STAR first-pass were 
used in STAR second-pass mapping to generate aligned BAM[54]. 
2.2.3 Gene Expression Analysis  
We used rsem-calculate-expression with default options in RSEM v1.2.21[55] to 
quantify mRNA expression in LS and FAP samples. RSEM transcript counts of all polyp and 
tumor samples were combined into a matrix and quantile-normalized using batch as a 
covariate. Normalized counts were transformed into log2 counts-per-million (CPM) with 
limma_3.30.9[56]. Genes linked to the immune microenvironment of CRC and MMR deficiency 
were grouped by lineage and/or function (Th1/Tc1, CTL, Th17, Treg, proinflammation, and 
metabolism) as previously reported[16] to distinguish which genes were differentially expressed 
on the basis of LS and FAP status. Differential expression of immune-related genes between 
FAP and LS polyps, and between LS hyper-mutant and LS non-hyper-mutant were assessed 
with Welch’s t-test and Benjamini & Hochberg multiple corrections. Significant genes were 
denoted as False Discovery Rate (FDR) <0.05. Differential expression of immune-related 
genes among FAP, LS polyps and LS carcinomas were performed with one-way ANOVA and 
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Tukey’s test. All statistical analyses were performed with stats package in R version 3.3.1. T-
cell signature enrichment score was calculated with GSVA_1.24.1[57] for FAP and LS polyps, 
LS tumors. Significant differences between groups were performed with one-way ANOVA and 
Tukey’s test. 
2.2.4 Mutation Analysis 
We followed GATK best practices on mutation discovery with RNA-Seq. We performed 
mark-duplicates, SplitNCigarReads and base-recalibration with GATK[58] v3.6 on STAR-
aligned BAM files. We called somatic mutations with MuTect2[39]. We decided to keep for 
further analysis as somatic mutation candidates all mutations denoted as “PASS” by MuTect2 
and that were not present in the thousand genome phase 3 data[59], the NHLBI GO Exome 
Sequencing Project (EVS; http://evs.gs.washington.edu/EVS/) or ExAC database [60], for 
which the reference allele and variant allele count were >2 and the allele frequency >5%. 
Mutations were annotated by Annovar[41] and Variant Tools[42]. Mutation rates were 
calculated by dividing the number of somatic mutations by the number of callable bases 
(defined as >10x in polyp and matched normal mucosa sample). Mutation signatures were 
detected and plotted with deconstructSigs_1.8.0[44] and hierarchical clustering of premalignant 
and malignant samples from our cohort and TCGA were performed with the same package. 
2.2.5 Neoantigen Discovery 
We used seq2HLA v2.213[61] with default settings to generate 4-digits HLA typing for 
MHC Class I and II on FAP and LS normal mucosa. Then, we ran pvac-seq v4.0.814[62] to 
generate neoantigen predictions on each polyps or tumor sample using the following 
parameters: (i) somatic mutation candidates from MuTect2, (ii) class I and II HLA 4-digit typing, 
(iii) NetMHCpan[63] and NetMHCpanII[64] for class I and II prediction, and (iv) epitope length 
of 8, 9, 10, 11 amino acids for class I and 15 for class II. We selected those neoantigens that 
required a binding affinity <500 nM, had allele frequency >5%, were expressed at a level >10 
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Transcripts per Million (TPM) and were not present in the 1,000 genomes database. We 
classified neoantigens based on their affinity in the following categories: strong if the binding 
affinity was <50 nM, medium if affinity was <100 nM, and weak if affinity was <500 nM. We 
performed canonical pathway comparison of neoantigens genes discovered in FAP and LS 
polyps with IPA. Selected pathways with P-values <0.05 were plotted. We assessed the 
difference in the number of neoantigens among FAP, LS non-hypermutant and hyper-mutant 
polyps, and LS carcinomas using Kruskal-Wallis test and Dunn’s multiple comparison test. 
2.3 Consensus Molecular Subtyping 
2.3.1 Patients and Samples 
We collected adenomatous (N=301) and serrated polyps (N=28 HPs and 60 SSAs) 
from sporadic and hereditary populations from a variety of sources: (1) an original institutional 
cohort from UTMDACC, (2) eight publicly available data sets from prior publications 
(GSE10714[65], GSE19963, GSE4183[66], GSE45270[29], GSE8671[67], GSE79462[68], 
GSE46513[69], GSE76987[70], GSE88945[71], GSE106500[72], GSE108317), and (3) 
proprietary data from Janssen Oncology (Table 5). Clinical information and raw gene 
expression data from publicly available data sets were retrieved from their original publications, 
data repositories, or by contacting the primary investigators. All patients and samples obtained 
from hereditary patients of UTMDACC were collected under approval of the institutional review 
board and written informed consent was obtained from all individuals. Archival samples across 
the CRC progression axis were obtained by Janssen Oncology from Avaden Biosciences and 
Asterand Biosciences under approved protocols from several institutions (Table 6). 
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Table 5 Data sets used in transcriptomic subtype analysis 
 
Source Platform AP HP SSA Total 
GSE10714 public Affy 2.0 5 11 0 16 
GSE19963 public Affy 2.0 0 5 0 5 
GSE4183 public Affy 2.0 14 0 0 14 
GSE45270 public Affy 2.0 7 0 6 13 
GSE8671 public Affy 2.0 31 0 0 31 
Avaden 1 proprietary Affy PM 60 0 11 71 
Avaden 2 proprietary Affy PM 136 0 9 145 
GSE79462 public Affy PM 9 0 7 16 
GSE46513 public Illumina 
HiSeq 
0 0 7 7 
GSE76987 public Illumina 
HiSeq 
10 10 20 40 
MDACC-
FAP 
public Illumina 
HiSeq 
16 0 0 16 
MDACC-LS public Illumina 
HiSeq 
13 2 0 15 
    Total 301 28 60   
Abbreviations: AP, adenomatous polyp; HP, hyperplastic polyp; SSA, sessile serrated polyp 
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Table 6. Clinical and pathological characteristics of patients belonging to cohorts 
Avaden 1 and Avaden 2 
Characteristics Avaden 1 Avaden 2 Total 
Samples n 71 145 216 
Gender female 36 74 110 
male 35 71 106 
Age (yr) mean 69.63 62.13 64.60 
  sd 11.72 13.33 13.27 
Pathology TA 20 26 46 
  TVA 28 74 102 
  TA with HGD 6 1 7 
  TA with CA 2 0 2 
  TVA with HGD 4 31 35 
  TVA with CA 0 4 4 
  SSA 11 9 20 
Location left 19 91 110 
  right 45 50 95 
  NA 7 4 11 
Size (mm) mean 20.49 12.53 15.12 
  sd 13.76 6.80 10.30 
Abbreviations: Tubular adenoma, TA; Tubulovillous adenoma, TVA; Sessile serrated adenoma, 
SSA; High grade dysplasia, HGD; Carcinoma, CA; 
  
  32 
2.3.2 Targeted Panel Sequencing 
Targeted panel sequencing on KRAS and BRAF was performed by Janssen Oncology 
in the Avaden 1 and 2 data set. Sequencing reads were aligned with BWA-mem[37] and 
mutations were detected with HaplotypeCaller from GATK version 3.4-46-gbc02625[73]. 
Mutations were annotated with Oncotator version 1.9.6.1[74]. 
2.3.3 Expression Data Processing 
We constructed cohort aggregated gene expression matrices for each data platform 
prior to downstream analysis. First, for RNAseq data, gene-level counts were generated using 
RSEM[55] and subsequently log transformed and quantile-normalized. We kept genes that 
were expressed in at least two-thirds of the samples. Second, for Affymetrix HGU133 Plus 2.0 
array data, each studies’ CEL files were aggregated and normalized with the single-sample 
frozen robust multi-array average (RMA) method from fRMA[75]. Probes were annotated with 
hgu133plus2frmavecs from R Bioconductor[76]. Multiple probes mapping to the same Entrez 
gene were aggregated using the 1st eigenvector from singular value decomposition (SVD). 
Third, for Affymetrix HGU133 Plus PM Array, each studies’ CEL files were normalized using the 
RMA method from the Bioconductor affy package[77]. Probes were annotated with HT_HG-
U133_Plus_PM.na36.annot.csv from the Affymetrix website. Multiple probes mapped to the 
same gene are combined using SVD. To correct for systematic batch differences across 
studies, we applied the ComBat[78] method implemented in the SVA[79] R package including 
polyp type as a covariate. For Affymetrix data, we used arrayQualityMetrics[80] R package to 
exclude outliers based on gene expression distribution and either distances between array or 
MA plot. For RNAseq data, we used a method based on Euclidean distances between 
samples. Outlier samples were excluded if their summed distances were > 2.5 standard 
deviations. We removed genes that were not common across the three aggregated expression 
matrices.  
2.3.4 Consensus Molecular Subtype Classification 
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We performed CMS classification on the polyp samples using the CMSclassifier R 
package[34]. CMS classification is assigned to the subtype with highest posterior probability. A 
list of curated gene sets previously identified by the CRC CMS consortium which consisted of 
ESTIMATE algorithm[81], curated signatures, canonical gene sets, immune activation, and 
metabolic action were used in the analysis[34]. For each aggregated data set, we first 
calculated differentially expressed genes between each CMS subtype as compared to other 
subtypes using limma_3.30.13[56]. Genes were ranked by –log(p-value) * fold change direction 
(1 if log fold change > 1 and -1 if log fold change <1). Then, we performed gene set enrichment 
analysis (GSEA) for each subtype using pre-ranked GSEA method from fgsea R package[82] 
with 10,000 permutations (Table S5-7). Gene sets with Benjamin-Hochberg adjusted p-value < 
0.05 were plotted (Fig S2-4). Benjamin-Hochberg adjusted p-value per gene set across 
aggregated data sets were combined using Fisher’s method to produce a combined enrichment 
analysis.  Clinical, pathological and molecular associations with CMS groups were performed 
using Fisher’s exact test by comparing each CMS subtype vs others. 
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3.1 Introduction 
Progression along the normal mucosa-adenoma-carcinoma sequence in CRC is 
fostered by progressive accumulation of genomic events in well-known driver genes with the 
truncal events being the acquisition of APC alterations in approximately 85% of cases [5]. The 
“Big Bang” model of colorectal carcinogenesis states that the vast majority of the genomic 
alterations accumulate during early stages of carcinogenesis and assumes that this massive 
accumulation happens after an initiating driver (APC) has occurred in a single crypt (founder 
clone)[83, 84]. Subsequent acquisition of driver mutations, such as KRAS, foster tumor 
progression and generation of subclones that will acquire additional mutations. Therefore, the 
“big bang” model of colorectal carcinogenesis implies a “monocryptal polyclonal” origin. 
However, the presence of multiple founder clones (lineages) from distinct crypts observed in 
both animal models and human samples [85-87] and challenges the monocryptal founder clone 
as origin of ITH.  
Next-generation sequencing technologies and bioinformatics tools have been widely 
adopted to deconvolve ITH[26, 27]. I hypothesize that inference on the number of tumor 
populations based on somatic mutations will determine the presence of clonality in 
premalignancy. In addition, I hypothesize origin of clonality in premalignant lesions is derived 
from multiple independent crypts that acquire distinct alterations in APC and KRAS. 
3.2 Results 
3.2.1 Evidence of clonality in WES 
I searched for evidence of clonality in APC-driven adenomas by visually inspecting the 
distribution of mutations ranked by allelic frequency. I observed 2 clusters of mutation allelic 
frequencies in 5 samples, suggesting the presence of 1 major clone and other minor subclones 
(Figure 1A). However, this type of analysis could be confounded by tumor purity and copy 
number variation. To mitigate the effect of variations in these 2 factors, I applied computational 
tools to transform the frequency distribution of mutations in each sample and to infer the 
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number of clones. I compared in silico estimations of purity, ploidy, and number of clones 
between adenomas and stage I CRC. The purity was significantly lower in adenomas 
compared with stage I CRCs (0.35 vs. 0.58, P < .0001; Figure 1B), as was the ploidy (1.93 vs. 
2.61, P < .0001; Figure 1C). Then, my analysis revealed the presence of multi-clonality in 18 
(72%) of 25 adenomas, with at least 1 major and 1 minor subclone per lesion. Moreover, more 
than 50% of the polyps from the same individual has estimated to have multiclonality. 
Interestingly, the number of clones estimated in adenomas was not significantly different from 
that for stage I CRC (1.72 vs. 2.06, P = .165; Figure 1D). 
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Figure 1. Clonality analysis of colorectal adenomas. A. Mutation counts detected by whole-
exome sequencing in 4 different adenomas, ordered by allelic frequency and provided as 
examples presenting evidence of clonality. B, C. Purity and ploidy of adenomas and stage I 
CRCs were estimated by the ABSOLUTE computational method (*P < .0001). D. Numbers of 
clones in adenomas were inferred by clustering cancer cell fraction of mutations estimated by 
ABSOLUTE. 
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3.2.2 Multiple somatic events detected in FAP Adenomas with high depth sequencing  
Next-generation sequencing at high depth using Ion Torrent AmpliSeq was performed in 
a total of 37 adenomas from 14 patients diagnosed with FAP to detect public somatic mutations 
in APC and KRAS (Figure 2). An advantage of studying adenomas of FAP patients with 
confirmed germline alterations of APC to detect hints of multiclonality is that one APC event is 
already given from the germline, so any new additional APC events will be acquired (somatic 
events under the assumption that adenomas are diploid). Therefore, accumulation of multiple 
somatic events either by mutation or allelic imbalance (loss of 5q) will be suggestive of 
polyclonality. The average sequencing depth obtained per sample for APC and KRAS was 
3,640x and 6,685x, respectively. I identified a total of 32 somatic events in APC with an 
average allelic frequency of 21%. The majority were mutations generating a stop codon (29 out 
of 32); although we detected other events such as a splicing mutation (c.1744-1G>A) and two 
missense mutations (c.2438A>G; p.Asn813Ser and c.2258A>G; p.His753Arg), which were all 
predicted to have a functional impact (). Using SNP arrays, loss of 5q was identified in 4 
adenomas with an average allelic frequency of 4% (Table 7). Overall, I was able to detect a 
second hit in APC in 81% of adenomas (30/37). Six adenomas (16%) presented double 
somatic events in APC in the form of two different mutations or the combination of one mutation 
associated with a 5q loss (Table 7). In addition, I detected 15 KRAS somatic mutations in 14 
adenomas with an average allelic frequency of 29%.  
One adenoma presented two different KRAS mutations: c.35G>A (p.Gly12Asp) and 
c.40G>A (p.Val14Ile) with allelic frequencies of 5% and 16%, respectively. Interestingly, this 
adenoma also presented 2 independent somatic events in APC: 5q loss and 
c.4464_4467delInsGTAAT (p.Leu1489*) (Table 7). APC alterations detected in one adenoma 
(MDAC33_P04) were selected to validate the multiclonal origin of these events using colony 
analysis. Of note, this adenoma was euploid and the region of APC containing the two somatic 
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mutations (c.4348C>T and c.4267_4280del) and the germline mutation (c.2894delA) was 
amplified and cloned into pGEM-T plasmid. A total of 100 colonies were genotyped and each 
colony carried a single mutational event: 25% were wild-type, 36% carried the germline 
mutation (c.2894del), 15% one of the somatic hits c.4348C>T and 24% the other somatic hit 
c.4267_4280del (Figure 3). These cloning results confirmed that the somatic APC mutations 
arose from separate and independent clones (polyclonal adenomas). 
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Figure 2. Experimental design and molecular analysis performed in bulk biopsies, crypts 
and whole lesion extracts of adenomas and colorectal carcinomas. Adenoma analyses 
were performed only in samples obtained from patients diagnosed with hereditary colorectal 
cancer syndromes. Carcinoma analysis were performed in a total of 6 tumors from sporadic 
cases and one tumor from a hereditary case. Note that both adenomas and carcinomas were 
analyzed from different locations of the colon. WES, whole exome sequencing. 
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Table 7. Analysis of APC, KRAS and 5q loss using AmpliSeq and SNP array. 
Sample 
APC somatic alterations 
  
Frequency 
KRAS somatic alterations 
  
Frequency 
cDNA protein  cDNA protein  
MDAC02_P02 
c.2438A>G p.Asn813Ser 
0.11 
      
c.4348C>T p.Arg1450* 
0.12 
MDAC02_P03 c.4234G>T p.Gly1412* 
0.07       
MDAC03_P01     
  
c.351A>T p.Lys117Asn 0.4 
MDAC03_P02 c.4348C>T p.Arg1450* 
0.24 
c.38G>A p.Gly13Asp 0.31 
MDAC03_P03 c.4348C>T p.Arg1450* 
0.16 
c.38G>A p.Gly13Asp 0.18 
MDAC10_P02 c.4330C>T p.Gln1444* 
0.08       
MDAC14_P04 c.4189G>T p.Glu1397* 
0.07       
MDAC14_P05 c.4219_4220del p.Ser1407* 
0.13       
MDAC17_P03 c.3925_3928del p.Glu1309Argfs*11 
0.13       
MDAC17_P04     
        
MDAC18_P02 c.1660C>T p.Arg554* 
0.06       
MDAC20_P02     
        
MDAC21_P01     
  
c.35G>T p.Gly12Val 0.09 
MDAC24_P01     
  
      
MDAC24_P02 5q loss 
0.02 
      
MDAC24_P03 c.2258A>G p.His753Arg 
0.04 
c.35G>T p.Gly12Val 0.37 
MDAC24_P04 c.847C>T p.Arg283* 
0.23 
      
MDAC24_P05 
c.1744-1G>A p.? 
0.13 
      
c.3340C>T p.Arg1114* 
0.04 
MDAC26_P01 
c.4135G>T p.Glu1379* 
0.46 
c.35G>T p.Gly12Val 0.09 
5q loss 
0.03 
   
MDAC26_P02 
c.4464_4467delinsGTAAT p.Leu1489* 0.36 c.40G>A p.Val14Ile 0.05 
5q loss 0.04 c.35G>A p.Gly12Asp 0.16 
MDAC26_P03 c.4508C>A p.Ser1503* 
0.37       
MDAC26_P04 
c.4099C>T p.Gln1367* 
0.45       
5q loss 
0.06 
   
MDAC26_P05 c.4348C>T p.Arg1450* 
0.39 
c.35G>A p.Gly12Asp 0.31 
MDAC29_P01 c.4037C>A p.Ser1346* 
0.30       
MDAC29_P02 c.4037C>A p.Ser1346* 
0.06       
MDAC32_P01     
        
MDAC32_P02 c.3916G>T p.Glu1306* 
0.27       
MDAC32_P03 c.4348C>T p.Arg1450* 
0.27 
c.35G>T p.Gly12Val 0.46 
MDAC33_P01 c.4267_4280del p.Leu1423Trpfs*10 
0.40 
c.57_58delinsT
T 
p.Leu19_Thr20delinsP
heSer 
0.62 
MDAC33_P02 c.4267_4280del p.Leu1423Trpfs*10 
0.40 
c.57_58delinsT
T 
p.Leu19_Thr20delinsP
heSer 
0.57 
MDAC33_P03 
c.4749_4754delinsCACG
T 
p.Met1583Ilefs*3 
0.33 
c.436G>A p.Ala146Thr 0.09 
MDAC33_P04 
c.4267_4280del p.Leu1423Trpfs*10 
0.14 c.57_58delinsT
T 
Leu19_Thr20delinsPh
eSer 
0.26 
c.4348C>T p.Arg1450* 
0.16 
MDAC33_P05 c.4267_4280del p.Leu1423Trpfs*10 
0.32 
c.57_58delinsT
T 
Leu19_Thr20delinsPh
eSer 
0.35 
MDAC34_P01 c.3766C>T p.Gln1256* 
0.08       
MDAC34_P02 c.4348C>T p.Arg1450* 
0.15       
MDAC34_P03 c.3340C>T p.Arg1114* 
0.17       
MDAC34_P04       
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Figure 3. A. Schematic representation of the multiple APC mutations identified in the adenoma 
selected for assessment of polyclonality by a cloning approach. The germline event is depicted 
in green and the somatic events are depicted in red; B. Frequency of colonies harboring wild-
type (wt), germline, and somatic mutated genotypes (mut). X-axis represents intensity of FAM 
fluorescence (wt allele) and Y-axis VIC fluorescence (mut allele). On the scatter plot diagrams, 
end signals from each sample have been presented as a single dot. (Cloning experiment was 
performed by Ester Borras.)   
  44 
3.2.3 Paired analysis of multi-region biopsies and crypts of adenomas and carcinomas 
reveal high degree of heterogeneity 
Next-generation sequencing results from whole lesion DNA extracts provided evidence 
that the mutational heterogeneity observed in adenomas was derived from multiple different 
clones containing distinct mutations in truncal driver genes. This leads to a hypothesis that ITH 
emerges early on colorectal carcinogenesis due to the interaction of multiple mutated crypts 
(independent lineages) that is not captured by bulk biopsies, thus requiring individual crypt 
analysis. Therefore, I decided to assess the presence of multiple somatic events in paired 
multi-region bulk biopsies and crypts extracted from the same lesions by applying ultrasensitive 
genotyping techniques within mutational hotspots of the APC and KRAS genes.  
APC analysis. Multi-region biopsy analysis revealed the presence of somatic APC 
mutations in almost all of the regions of 2 adenomas from the FAP and UFP2 cases (Figure 4, 
and Supplementary Figure S3 and Table S7 in Gausachs M, Chang K, et al. "Mutational 
Heterogeneity in APC and KRAS Arises at the Crypt Level and Leads to Polyclonality in Early 
Colorectal Tumorigenesis". Clin Cancer Res. (2017)). Crypt analysis of these adenomas 
revealed mixtures of novel somatic APC alleles, which were not present in the bulk biopsies, 
and also an abundance of wild-type alleles of the MCR of APC. The percentage of crypts with 
APC mutations varied across adenomas but overall there was a predominance of wild-type 
ones (average 20%, range 13-100%). In contrast, adenomas from the MAP and UPF1 cases 
showed a good correlation between bulk biopsy and crypt analyses with all the biopsies and 
crypts displaying a wild-type status for the MCR region of APC (Figures S1-2 and Table S7 in 
Gausachs M, Chang K, et al. "Mutational Heterogeneity in APC and KRAS Arises at the Crypt 
Level and Leads to Polyclonality in Early Colorectal Tumorigenesis". Clin Cancer Res. (2017)).  
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Figure 4. APC and KRAS genotyping of crypts and bulk biopsies in adenomas from the 
FAP case. On the left side is displayed the study of the mutator cluster region (MCR) of APC 
performed in 3 adenomas (Ad1.1, Ad2.1, and Ad3.1). The upper panel shows the results of the 
bulk biopsy analysis and the lower panel the results obtained from crypts that correspond to the 
same lesions. On the right side are presented the results of the KRAS genotyping. Each 
column represents one of the KRAS hotspot mutations that were tested by the digital or the 
dynamic array, and each row represents the results of bulk biopsies (one biopsy per adenoma, 
upper panel) or single crypts (10 crypts per adenoma, lower panel). The upper panel shows the 
digital PCR results from bulk biopsies, which identify a single KRAS mutation at low frequency 
in each adenoma.  
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KRAS analysis. In general, all bulk biopsies analyzed in adenomas from the MAP, 
UFP1 and UFP2 cases unveiled multiple co-existing KRAS mutations (mutational load average 
11%) while FAP adenomas only harbored single mutations (Figure 4, Supplementary Figure 
S1-3 and Table S8 in Gausachs M, Chang K, et al. "Mutational Heterogeneity in APC and 
KRAS Arises at the Crypt Level and Leads to Polyclonality in Early Colorectal Tumorigenesis". 
Clin Cancer Res. (2017)). However, when I studied crypts obtained from the same lesions a 
striking intra-crypt mutational heterogeneity was evident in 76% of adenomas (13/17). An 
average of 44% of the crypts per adenoma displayed multiple KRAS mutations (range 10-
100%) and the proportion of mutant alleles was much higher compared to the bulk biopsies 
(average 26%, versus 7.6%). Moreover, I also observed KRAS mutational heterogeneity in the 
matched surrounding normal mucosa that may reflect a ‘genetic field effect’, which may be 
acquired prior to the APC alterations or as a consequence of underlying deficiencies in DNA 
repair that are the basis of these syndromes.  
A high great degree of consistency between the results of bulk biopsies and crypts in 
terms of KRAS mutational diversity and proportion of mutated alleles was observed among 
carcinomas (29% in biopsies versus 22% in crypts). In this regard, no additional mutations 
were detected in the crypts analyzed. However, in terms of mutational load, the proportion of 
KRAS mutant alleles among crypts was variable (Figure 5, supplementary Table S8 in 
Gausachs M, Chang K, et al. "Mutational Heterogeneity in APC and KRAS Arises at the Crypt 
Level and Leads to Polyclonality in Early Colorectal Tumorigenesis". Clin Cancer Res. (2017)). 
Intriguingly, several carcinomas (SP2, SP3 and SP6) have a variable fraction of wild-type 
KRAS crypts that co-existed with crypts with a high KRAS mutational load, depicting another 
level of genetic heterogeneity.  
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Figure 5. APC and KRAS genotyping of crypts and bulk biopsies from sporadic 
colorectal carcinoma case #6 (SP6). 
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In an effort to provide a complete picture of the evolutionary dynamics of APC and 
KRAS mutations in all pathways of carcinogenesis in CRC, two different hereditary cases 
displaying MMR deficiency were included. We analyzed one adenoma from a patient with 
CMMR-D and one carcinoma from an unrelated Lynch Syndrome patient (Table S2). The bulk 
biopsy analysis in these two samples was limited to one biopsy rather than being multiregional 
as in the rest of hereditary adenomas and sporadic tumors included in this report. The analysis 
of the MCR of APC in both cases did not reveal any mutation at the biopsy and crypt level 
(Figure S4 and Table S7 in Gausachs M, Chang K, et al. "Mutational Heterogeneity in APC and 
KRAS Arises at the Crypt Level and Leads to Polyclonality in Early Colorectal Tumorigenesis". 
Clin Cancer Res. (2017)). Absence of heterogeneity with a predominance of wild-type KRAS 
crypts was observed in the adenomas while the carcinoma showed a relatively low level of 
heterogeneity among the crypts (Figure S4 and Table S8 in Gausachs M, Chang K, et al. 
"Mutational Heterogeneity in APC and KRAS Arises at the Crypt Level and Leads to 
Polyclonality in Early Colorectal Tumorigenesis". Clin Cancer Res. (2017)). Therefore, APC and 
KRAS analysis did not capture mutational heterogeneity in MMR deficient lesions but these 
results do not rule out that polyclonality that may be observed by alternative studies analyses 
other drivers more relevant to MMR deficient carcinogenesis. Nonetheless, these results 
reinforce the robustness of our technical approach as it did not observe any random variation 
among the MMR deficient samples, thus providing a negative control. 
3.2.4 Hierarchical clustering of crypts reveals a striking degree of non-random inter-
crypt heterogeneity with several crypt metapopulations 
Unsupervised clustering of all crypts based on KRAS mutations for each patient 
revealed a non-random pattern (Figure 5 and Figures S8-11). A discrete and similar number of 
metapopulations was evident in both adenomas (mean 3.80 metapopulations per case) and 
carcinomas (mean 2.84 metapopulations per case). This fact reflects that a stable number of 
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founder clones emerge early in carcinogenesis and remains stable during progression of 
carcinogenesis. 
Crypts from MAP, UFP1 and UFP2 cases clustered around 9, 2 and 4 metapopulations, 
respectively, compared to FAP, which showed 2 main ones (Figure 5 and Figure S8). The 
difference observed between the number of clones in MAP and FAP may be related to the 
mechanism of genetic instability (driven by deficiency in base excision repair versus 
chromosomal instability). Particularly striking was the fact that crypts from adenomas that were 
physically located at different parts of the colon clustered together, once again pointing towards 
the existence of a ‘genetic field’ effect.
 
3.3 Discussions 
In this chapter, I used computational tools to identify the presence of polyclonality in 
FAP adenomas. The number of tumor populations between adenomas and stage I CRC is not 
significantly different, which suggests that polyclonality originates early in carcinogenesis and 
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not from late clonal expansions. This observation is consistent with the “big bang” model of 
colorectal carcinogenesis.  
In addition, I have uncovered the presence of multiple co-occurring somatic APC 
mutations using whole lesion extracts from colorectal adenomas of FAP patients, which is 
consistent with previous observations[88]. However, using cloning approaches we have 
confirmed for the first time that they belong to independent clones. Furthermore, the fact that is 
observed only in pre-malignant samples, which have not acquired yet chromosomal instability 
and are still diploid, confirms that the theory of the presence of ‘three-hits’ inactivating APC is 
still plausible in carcinomas that may have acquired multiple copies of APC[89]. 
Furthermore, I have detected the presence of mutational heterogeneity in APC at the 
crypt level among early stage adenomas with only a minority of the crypts harboring the clonal 
APC mutation identified in their paired bulk biopsies. The majority of crypts from adenomas 
were APC wild-type. Both results are in line with previous observations made in more 
advanced lesions such as adenoma-in-carcinoma samples, where the degree of heterogeneity 
was higher, and only a minority of crypts were wild-type[87]. This is not unexpected and reflects 
further progression into the clonal evolution presented in more advanced stages of carcinoma 
progression.  The fact that we have consistently identified wild-type APC crypts in the 
intraluminal surface of carcinomas and adenomas distal to normal mucosa is compatible with 
the coexistence of normal crypts inside of the dysplastic cancerous mass that, based on the 
work of Thliveris et al, could represent wild-type crypts recruited by the mutant APC founder 
clone to foster neoplastic growth through transformation later on[87].  
The KRAS genotyping analysis using digital PCR has detected a striking degree of 
heterogeneity at the biopsy and crypt levels within adenomas and carcinomas, which is in line 
previous results that used less sensitive techniques with lower resolution[52, 90]. Clustering 
analysis has revealed that the observed KRAS mutational pattern in crypts was not random 
and depicted the presence of a limited number of crypt metapopulations in adenomas and 
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carcinomas. It was notable that crypts obtained from distinct adenomas arising from hereditary 
patients displayed a similar mutational pattern, irrespective of the location of the lesion 
consistent with a ‘genetic field effect’. There are several factors that could explain this 
observation: (i) the asymmetric expansion associated to crypt fission or other mechanisms of 
crypt interactions yet to be determined[91, 92]; (ii) the underlying mechanism of genetic 
instability present in hereditary cases such as chromosomal instability in FAP, base excision 
repair deficiency in the case of MAP, and MMR deficiency in Lynch syndrome and CMMRD 
(38), the latter being notorious for an absence of KRAS heterogeneity. However, we cannot 
rule out that at least part of these KRAS mutations emerge prior to the acquisition of APC 
mutations and the establishment of a founder clone. In fact, KRAS mutations have been 
detected in normally appearing tissues and in aberrant crypt foci that may not progress into 
adenomas (39). Lastly, this diversity of KRAS mutations acquired early in carcinogenesis has 
multiple ramifications for the design of chemoprevention strategies and to explain the 
emergence of resistance to therapies. 
Our study has several limitations. First, the mechanical isolation of crypts is subject to 
sampling bias and selection of specific cell populations. However, we believe that we have 
minimized this problem by involving dedicated expert gastrointestinal pathologists to collect 
samples following established procedures that are unlikely to be contaminated by normal 
crypts. Second, performing genomic analysis in relatively small groups of cells is challenging 
due to the limited amounts of DNA rendered. We have evaluated different approaches (whole 
genome amplification versus nested PCR) to amplify the nucleic acid material prior to our 
ultrasensitive genotyping and demonstrated that our approach using nested PCR is capable to 
render robust analytical results. Furthermore, all of our tests have been performed in 
sextuplicate and included multiple internal controls, thus minimizing uncertainty. Therefore, we 
are confident that this rigorous and reproducible approach minimizes concerns for 
contamination. Third, in our crypts analysis we have only assessed the MCR of APC and 
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therefore the possibility that we have missed mutations located outside of this region reflecting 
additional heterogeneity is obvious. In the future, single cell sequencing analysis will be the 
most appropriate tool to interrogate the dynamics and clonal heterogeneity of crypts in 
premalignancy, thus helping to clarify the level of mutational diversity within the crypt and 
establishing a cellular hierarchy based on mutational events[93]. 
Taken together, the body of evidence presented here demonstrates that the presence of 
ITH in colorectal premalignancy is abundant and secondary to the presence of multiple 
independent lineages derived from crypt progenitors, which is highlighted by the mutational 
heterogeneity detected in APC and KRAS. 
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Chapter 4 IMMUNE PROFILING OF PREMALIGNANT LESIONS IN PATIENTS WITHLYNCH 
SYNDROME 
The content of this chapter is based on the following publication[72]: 
Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San 
Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz 
S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E. Immune Profiling of Premalignant 
Lesions in Patients With Lynch Syndrome. JAMA Oncol. 2018 Apr 16. doi: 
10.1001/jamaoncol.2018.1482. PubMed PMID: 29710228. 
Copyright 2018 by JAMA Oncol. Reproduced with permissions of JAMA Oncol via Copyright 
Clearance Center. 
 
  
  55 
4.1 Introduction 
LS is the most common hereditary CRC syndrome and represents a model to study 
carcinogenesis in the background of DNA mismatch repair deficiency, which is the basis of 
approximately 15% of sporadic CRC. MMR deficiency causes an excessive number of frame-
shift mutations that generates neoantigens and infiltration by immune T-cells. Neoantigens are 
thought to induce an upregulation of checkpoint molecules such as PD-1, PD-L1, and LAG3 to 
counter balance infiltrating T-cells and allow the continual progression of tumor[16]. In fact, 
checkpoint inhibitors Pembrolizumab and Nivolumab have demonstrated clinical utility in 
extending progression free and overall survival of patients with MMR-deficient tumors[18-20]. In 
order to investigate the potential opportunity for immuno-prevention in LS patients, we 
proposed this study to assess the expression levels of immune checkpoints and T-cell 
infiltration in premalignant lesions of LS patients. We hypothesized that MMR-deficient lesions 
display an up-regulation of immune checkpoints compared to MMR-proficient lesions. I 
addition, we proposed that mutational load and neoantigen formation arise late in MMR-
deficient carcinogenesis (either advanced premalignant lesions or carcinomas) and they are 
independent of the immune-profile displayed by premalignant lesions. 
4.2 Results 
4.2.1 LS premalignancy display a unique immune signature 
RNA-sequencing (RNA-seq) was performed in a total of 28 colorectal polyps (Table 8). 
All of the polyps analyzed from FAP patients (n=17) were confirmed to be early tubular 
adenomas, smaller than 1 cm in diameter, and without signs of high-grade dysplasia. All LS 
polyps (n=11) were early adenomas of 1 cm in diameter, with the exception of 2 that were 
hyperplastic polyps. A total of 4 LS polyps displayed MMR deficiency by loss of staining in 
MSH2 and/or MSH6, and the rest were MMR proficient (Table 9). Overall, LS polyps showed a 
significantly higher expression of CD4, IFNG, LAG3 and CD274/PDL1 (Checkpoints), IL12A 
and TNF (Pro-inflammatory) when compared with FAP polyps and displayed a consistent trend 
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among the genes integrated in these pathways regardless of their MMR status (Figure 6). 
Interestingly, LAG3 was observed to be the most significantly upregulated. Then, we analyzed 
the evolution of immune activation in MMR carcinogenesis by comparing LS polyps to 
carcinomas and observed additional consistent activation among genes in the Proinflammatory 
and Metabolism pathways that were absent in premalignancy (Figure 7A). Of note, LS 
premalignancy showed activation of both PD-L1 and LAG-3 and carcinomas showed 
deregulation of additional checkpoints such as CTLA4. This expression pattern displayed by LS 
polyps and carcinomas is consistent with a strong enrichment for additional immune related 
gene sets such as Immune Activation, Immune Response, PD-1 activation and T-cell reaction 
(Figure 7B)[94]. These results suggest the existence of a robust immune microenvironment in 
LS premalignancy secondary to T-cell infiltration[16].  
  
  57 
Table 8 Clinical characteristics of FAP and LS patients 
Patient  Gender Age Race 
Colorectal 
Sx 
Polyps 
detected 
Cancer Dx 
Germline mutation 
Gene gDNA 
FAP_1 M 35 W IRA >100   APC c.1880dupA 
FAP_2 M 33 W IRA <5   APC c.3810T>A 
FAP_3 F 42 W IRA 5   APC del exon 14 
FAP_4 M 42 W P >100 HCC, D APC c.622C>T 
FAP_5 F 40 W IRA 5   APC del exons 8-9 
FAP_6 M 37 W IRA <5   APC c.1658G>A 
FAP_7 M 65 W IRA <50   APC c.477C>G 
FAP_8 F 25 AA NP >100 D APC c.4733_4734del  
FAP_9 F 28 W IRA >100 EC, OC APC c.847C>T 
FAP_10 F 25 W P >100   APC c.3810T>A 
LS_1 M 53 W RH 1 CC MSH6 c.3744_3773del30 
LS_2 F 46 W NP 3 EC MSH2 c.687delA 
LS_3 M 52 W LH 1 CC PMS2 del exon 14 
LS_4 F 37 W NP 1   MSH2 c.1034G>A 
LS_5 F 53 W NP 1   MSH2 c.1661+1G>A 
LS_6 M 58 W NP 2   MSH2 del exons 1-6 
LS_7 M 76 W LH 2 CC MSH2 c.1216C>T 
LS_8 F 68 W NP 4 EC MSH6 c.3238_3239delCT 
LS_9 F 62 W NP 1 EC MSH6 c.3860ins4 
LS_10 F 43 W RH 3 CC MSH6 c.2645_2653delTTAAGTCTA 
LS_11 F 63 W TCR 3 CC, EC MSH6 c.3699_3702delAGAA 
LS_12 F 35 W SC 0 CC MLH1 c.1279C>T 
LS_13 F 76 W SC 0 CC, BC, GIST MLH1 c.1918C>T 
LS_14 F 61 W RH 0 CC PMS2 c.2059C>T 
Abbreviations: M, male; F, Female; W, white; AA, African-American; IRA, ileorectal anastomosis; P, pouch; RH, right 
hemicolectomy; LH, left hemicolectomy; TCR, transverse colon resection; SC, subtotal colectomy; NP, not performed; NA, not 
available; CC, colon cancer; HCC, hepatocellular carcinoma; HepBI, hepatoblastoma; D, desmoid; EC, endometrial cancer; OC, 
ovarian cancer.  *Denotes Hispanic ancestry. 
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Table 9 Pathology characteristics of FAP and LS polyps 
Patient ID Sample ID Type Pathology Location Size/T
NM 
IHC-MSH2 IHC-MSH6 IHC-MLH1 IHC-PMS2 
FAP_1 FAP_G2 FAP TA R 5-10 NA NA NA NA 
FAP_1 FAP_G3 FAP TA R 5-10 NA NA NA NA 
FAP_2 FAP_G53 FAP TA R <5 NA NA NA NA 
FAP_2 FAP_G55 FAP TA R <5 NA NA NA NA 
FAP_3 FAP_G5 FAP TA R <5 NA NA NA NA 
FAP_3 FAP_G6 FAP TA R <5 NA NA NA NA 
FAP_4 FAP_G13 FAP TA R 5-10 NA NA NA NA 
FAP_4 FAP_G14 FAP TA R 5-10 NA NA NA NA 
FAP_4 FAP_G15 FAP TA R 5-10 NA NA NA NA 
FAP_5 FAP_G25 FAP TA R <5 NA NA NA NA 
FAP_6 FAP_G29 FAP TA R NA NA NA NA NA 
FAP_7 FAP_G39 FAP TA R <5 NA NA NA NA 
FAP_8 FAP_G47 FAP TA R <5 NA NA NA NA 
FAP_8 FAP_G48 FAP TA R <5 NA NA NA NA 
FAP_9 FAP_G67 FAP TA R 5-10 NA NA NA NA 
FAP_10 FAP_G61 FAP TA NA NA NA NA NA NA 
LS_1 LS_EBL1 LS TA D 5-10 Intact Intact NA NA 
LS_2 LS_EBL3 LS TA A <5 Intact Intact NA NA 
LS_3 LS_EBL5 LS HP D 5-10 NA NA Intact Intact 
LS_4 LS_EBL7 LS TA with HGD D >10 Lost Lost NA NA 
LS_5 LS_EBL9 LS TA R 5-10 Lost Lost NA NA 
LS_6 LS_EBL11 LS TA A >10 Lost Lost NA NA 
LS_7 LS_EBL13 LS TA A 5-10 Intact Intact NA NA 
LS_8 LS_EBL18 LS HP D 5-10 Intact Intact NA NA 
LS_9 LS_EBL26 LS TA D 5-10 NA Intact NA NA 
LS_10 LS_EBL20 LS TA D 5-10 Intact Lost NA NA 
LS_11 LS_EBL23 LS TA A <5 Intact Intact NA NA 
LS_12 LS_T3 LS CA D pT3N0 Intact Intact Lost Lost 
LS_13 LS_T2 LS CA D pT4aN
0 
Intact Intact Lost Lost 
LS_14 LS_T1 LS CA A pT2N0 Intact Intact Intact Lost 
Abbreviations: TA, tubular adenoma; HP, hyperplastic polyp; HGD, high grade dysplasia; A, 
cecum/ascending/hepatic flexure; D, transverse/descending/sigmoid; R, rectum/rectosigmoid; NA, not assessed. 
Assessment of expression of MMR proteins in LS polyps was  based on the already known germline mutations. 
Therefore, only the protein pair matching the germline mutation was performed.  
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Figure 6 mRNA expression levels of immune-related genes involved in CD4, Th1/Tc1, 
CTL, checkpoint response, TH17, Treg, Proinflammation and Metabolism comparing LS 
and FAP polyps. The graphs display means for each group and statistically significant 
difference between FAP and LS (*P<0.05, **P<0.01, ***P<0.001), using Welch’s t-test and 
multiple comparisons by Benjamini-Hochberg method. 
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Figure 1. Immune profile of Lynch syndrome premalignancy. 
mRNA expression levels of immune-related genes involved in CD4, Th1/Tc1, CTL, checkpoint response, TH17, Treg, 
Proinflammation and Metabolism comparing LS and FAP polyps. The graphs display mean for each group and statistically 
significant difference between FAP and LS (*P<0.05, **P<0.01, ***P<0.001), using Welch’s t-test and multiple comparisons 
by Benjamini-Hochberg method. 
Figure 1
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Figure 7. A. mRNA expression levels of immune-related genes involved in CD4, Th1/ Tc1, 
CTL, checkpoint response, TH17, Treg, Proinflammation and Metabolism comparing LS 
polyps and LS tumors; B. T-cell signature enrichment score comparing LS and FAP 
polyps, LS tumors. The graphs display means for each group and statistically 
significant difference between each group using ANOVA and Tukey’s Test, and 
multiple comparisons by Benjamini & Hochberg method (*P<0.05, **P<0.01, 
***P<0.001). 
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4.2.2 Hypermutated LS polyps are associated with mismatch repair-deficient mutation 
signature 
Based on the previous findings made in carcinomas, we hypothesized that one possible 
explanation for the immune deregulation observed in LS premalignancy is the acquisition of 
high levels of somatic mutations (hypermutation). In order to assess the mutation rate in our 
samples, we called mutations from RNA-seq data and compared the results to hyper- and non-
hypermutant sporadic carcinomas from The Cancer Genome Atlas (TCGA) and our LS 
carcinomas. To this end, we first demonstrated the feasibility of using RNA-seq to estimate 
somatic mutation rates by observing a statistically significant correlation between mutation 
rates called from whole exome sequencing (WES) data and RNA-seq in 47 TCGA samples 
with matched data (R2=0.339, P-value<0.001). Overall, polyps displayed low mutation rates 
compared to carcinomas; however, among LS polyps 3 were found to be hypermutated (Figure 
8A), and exhibited a mutation signature with distinct C>T changes that are associated with 
deficiency in the DNA MMR system[95]. These 3 hyper-mutant LS polyps clustered with 
sporadic hyper-mutant CRCs from TCGA and LS carcinomas based on mutation signature 6 
(Figure 8B, Figure 9) and displayed loss of staining of MMR proteins (i.e. MMR deficiency, 
Table 9). At the same time FAP polyps and non-hypermutated LS polyps shared a similar 
mutation spectrum lacking the distinct MMR-deficient pattern. Furthermore, a comparative 
analysis of the immune profile of hyper-mutant and non-hypermutant LS polyps was only 
significant for the Treg-related gene FOXP3 and the immune checkpoint CTLA4 (Table 10). We 
confirmed with immunohistochemistry the prominent infiltration by FOXP3 positive T-cells of 
hyper-mutant LS polyps (Figure 10). This fact suggests that the immune activation program 
that is displayed by all LS polyps of this cohort (both hyper- and non-hypermutant) is 
independent of the mutation rate. 
 
  62 
 
Figure 8. Mutational rate and mutation signature distribution in Lynch syndrome 
premalignancy. A. Comparisons of mutation rate among FAP, hypermutated and non-
hypermutated LS polyps, hypermutated LS, and TCGA tumors. The graphs display 
means for each group and statistically significant differences between groups 
(*P<0.05, **P<0.01, ***P<0.001); B. Hierarchical Clustering of mutation spectrum of 
FAP and LS polyps, LS Tumors and sporadic TCGA CRC stage I and II colorectal 
tumors with known MSI and hypermutation status. A total of 3 hypermutated LS 
polyps, 1 LS tumor and 4 hypermutated TCGA tumors display mutational signature 6, 
which is caused by defective DNA MMR. 
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Figure 9. Mutation Spectrum of FAP and LS polyps. Note that LS adenomas with 
hypermutation displayed a higher proportion of C>T changes as well as a different 
profile of T>C changes. 
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Table 10. Immune profile of LS polyps classified by mutational rate (hyper- versus non-
hypermutant. Genes linked to the immune microenvironment of CRC and MMR 
deficiency were grouped by lineage and/or function (Th1/Tc1, CTL, Th17, Treg, 
proinflammation, and metabolism) as previously reported by Llosa et al, Cancer 
Discovery (2016). A total of 3 LS polyps were found to be hypermutant and 8 non-
hypermutant. Expression values are expressed in counts per million. The statistical 
tests were performed on log2-transformed CPM. Welch's t-Test and multiple 
correction by Benjamini & Hochberg were used (FDR<0.05). Significantly different 
genes are in bold. Abbreviations: Hyper, Hypermutant. 
Gene 
LS Hypermutant 
Mean 
LS Non-
hypermutant 
Mean 
LS Hyper- vs Non-
hypermutant FDR 
LS Hyper- vs Non-
hypermutant p-value 
CD4 42.268 47.382 0.8453 0.6574 
IFNG 0.141 0.167 0.9375 0.8565 
TBX21 0.693 0.918 0.7547 0.3808 
CD8A 6.919 9.970 0.7547 0.4472 
GZMB 1.342 1.435 0.8860 0.7219 
PRF1 4.051 4.313 0.9375 0.8613 
IL21 0.039 0.052 0.9375 0.9375 
IL17A 0.081 0.083 0.9375 0.9242 
RORC 37.285 43.126 0.8295 0.5372 
IL23A 0.573 0.667 0.9375 0.9101 
FOXP3 2.839 1.291 0.0466 0.0017 
IL10 1.880 3.036 0.0651 0.0145 
TGFB1 18.171 14.693 0.7204 0.2935 
PTGS2 5.660 2.590 0.0789 0.0205 
IL1B 4.935 4.907 0.8295 0.5530 
IL18 33.313 71.735 0.0520 0.0058 
IL6 0.446 0.233 0.7547 0.4226 
IL12A 0.439 0.599 0.2647 0.0882 
TNF 2.024 3.085 0.3795 0.1405 
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CTLA4 2.281 1.045 0.0495 0.0037 
PDCD1 1.283 1.163 0.7547 0.3759 
LAG3 2.654 2.925 0.8453 0.6361 
CD274 3.039 3.752 0.7547 0.3989 
IDO1 10.619 8.295 0.8453 0.6166 
NOS2 27.165 18.278 0.1003 0.0297 
HIF1A 142.719 98.423 0.0651 0.0129 
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Figure 10. Immunohistochemical staining of CD4 and FOXP3 of a representative 
hypermutant Lynch syndrome polyp showing abundant infiltration by CD4 
positive/FOXP3 positive T-cells. 
  
eFigure 4
eFigure 4. Immunohistochemical staining of CD4 and FOXP3.
Representative hypermutantLynch syndrome polyp show ing abundant inf iltration by CD4 positive/FOXP3 positiveT-cells.
CD4 FOXP3
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4.2.3 The number of neoantigens is correlated with mutation rates but not associated 
with the immune expression profile 
We postulated that the immune profile observed in all LS polyps could be secondary to 
an increase in neoantigen rate that is independent from the global mutational rate. To 
determine this, we performed MHC class I and II typing and detected tumor-specific 
neoantigens using bioinformatic methods[62, 96]. The 3 hypermutated LS polyps displayed a 
neoantigen burden that was similar to that for LS carcinomas and higher than for the non-
hypermutant LS and FAP polyps (Figure 11). This difference was statistically significant for 
both high- and low-binding affinity neoantigens binding MHC class I and II (Figure 12A, B) and 
secondary to the accumulation of indels (Figure 12C, D). Overall, the total number of 
neoantigens in FAP samples did not vary as a function of the mutational rate (R2=0.02) but it 
did correlate well in LS polyps (R2=0.8, P-value<0.001, Figure 12E, F). These analyses confirm 
that a higher neoantigen load is secondary to an increase in mutational rate in hyper-mutant LS 
polyps but this is not responsible for the overall immune profile displayed by LS premalignancy. 
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Figure 11. Total number of MHC class I and II neoantigens in FAP, LS polyps and LS 
tumors. Each column represents a sample with MHC class I neoantigens in shades 
of blue stratified by binding affinity and MHC class II in shades of grey. Neoantigens 
selected had <500 nM >5% allele frequency, were expressed at >10 Transcripts per 
Million (TPMs), and were not found in 1,000 genomes database.  
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Figure 12. MHC Class I and II neoantigens in Lynch syndrome and FAP 
premalignancy, and LS carcinomas. A,B Predicted number of MHC class I and II 
neoantigens (<500nM and >5% AF and not in 1kg and >10 TPM) of FAP and LS 
polyps, LS tumors; C,D Number  of InDels in MHC class I and II predicted 
neoantigens; E,F Mutation rate vs predicted number of MHC class I and II 
neoantigens; Statistical differences  between each groups are performed with 
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Kruskal-Wallis and Dunn’s Test. (*P<0.05, **P<0.01, ***P<0.001); G. fold-change of 
CTNNB1 mRNA level between  FAP, LS polyps and matched normal mucosa. 
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4.2.4 LS premalignancy display neoantigens in additional DNA repair pathways and 
FAP in WNT/β-catenin 
We proceeded to discover gene pathways affected by emerging neoantigens unique to 
LS premalignancy using Ingenuity Pathway Analysis (IPA). Among the most significant 
pathways enriched by both class I and II neoantigens, we identified alterations in DNA repair 
mechanisms that could contribute to additional accumulation of somatic mutations in advanced 
LS polyps and carcinomas such as the role of BRCA1 in DNA damage response and ATM 
signaling (Figure 13). On the other side, FAP polyps acquired neoantigens in the WNT pathway 
(Figure 13) and also accumulated somatic genomic events in APC (Table 11). As it has been 
recently suggested, the activation of β-catenin (CTNNB1) secondary to deregulation of the 
WNT pathway is responsible for immune exclusion in carcinomas[94]; therefore, we decided to 
assess the expression levels of CTNNB1 in our samples and found that all FAP polyps 
presented with WNT/β-catenin activation compared to normal adjacent mucosa. In contrast LS 
polyps did not display any significant activation of CTNNB1, thus supporting the contribution of 
WNT/β-catenin to immune exclusion in FAP premalignancy (Figure 12G). However, in the 
absence of high neoantigen rates and MMR deficiency the mechanism responsible for the 
immunoactivation in LS premalignancy remains elusive. 
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Figure 13. Pathway analysis of neoantigens present in FAP, LS polyps and LS Tumors. 
MHC class I and II neoantigens were selected with <500nM binding affinity and >5% 
allele frequency and expressed at >10 TPMs and were not found in 1,000 genomes 
database. Only selected pathways with enrichment for both MHC class I and  II 
neoantigens are displayed. Complete list of pathways can be found  eTable9 in Chang 
K, et al. “Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome”. JAMA 
Oncol. 2018 Apr 16. doi: 10.1001/jamaoncol.2018.1482. 
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Figure 4. Pathway analysis of neoantigens pr esent in FAP, LS polyps and 
LS Tumors. MHC class I and II neoantigens were selected with <500nM binding af finity and >5% allele 
frequency nd expressed at  >10 TPMs nd were not found in 1,000 genomes database. Only selected 
pathways with enrichment for both MHC class I a nd II neoantigens are displayed. Complete list of 
pathways can be found in eTable 9.
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Table 11. Germline and somatic mutation detected in FAP and LS polyps. 
Mutational data derived from RNA-seq analysis. Sample FAP_G53 and LS_EBL26 
harbored APC LOH in 5q in addition to the somatic mutations.  
Sample ID  Type Patient ID Mutation Gene cDNA Protein 
Germline 
Validation 
FAP_G2 FAP FAP_1 Germline APC c.1880dupA p.Ala630* Yes 
FAP_G3 FAP FAP_1 
Germline APC c.1880dupA p.Ala630* Yes 
Somatic 
APC c.4473_4474delinsGC 
p.(Phe1491_Ala1492del
insLeuPro) 
  
Somatic KRAS c.519T>C p.(=)   
FAP_G53 FAP FAP_2 
Germline APC c.3810T>A p.Cys1270* Yes 
Somatic APC c.2438A>G p.(Asn813Ser)   
Somatic APC c.4348C>T p.(Arg1450*)   
FAP_G55 FAP FAP_2 Germline APC c.3810T>A p.Cys1270* Yes 
FAP_G5 FAP FAP_3 
Germline APC del exon 15 p.? No 
Somatic APC LOH 5q     
FAP_G6 FAP FAP_3 Germline APC del exon 16 p.? No 
FAP_G13 FAP FAP_4 
Germline APC c.622C>T p.Gln208* Yes 
Somatic APC c.4057G>T p.(Glu1353*)   
Somatic APC c.4135G>T p.(Glu1379*)   
FAP_G14 FAP FAP_4 Germline APC c.622C>T p.Gln208* No 
FAP_G15 FAP FAP_4 
Germline APC c.622C>T p.Gln208* Yes 
Somatic APC c.4189_4190del p.(Arg1399Phefs*9)   
Somatic APC LOH 5q     
FAP_G25 FAP FAP_5 Germline APC del exons 8-10 p.? No 
FAP_G29 FAP FAP_6 Germline APC c.1658G>A p.Trp553* Yes 
FAP_G39 FAP FAP_7 Germline APC c.477C>G p.Tyr159* No 
FAP_G47 FAP FAP_8 
Germline APC c.4733_4734del  p.Cys1578Tyrfs*13 No 
Somatic APC LOH 5q     
FAP_G48 FAP FAP_8 Germline APC c.4733_4734del  p.Cys1578Tyrfs*14 No 
FAP_G67 FAP FAP_9 
Germline APC c.847C>T p.Arg283* No 
Somatic APC c.4135G>T p.(Glu1379*)   
Somatic KRAS c.35C>A p.(Gly12Val)   
FAP_G61 FAP FAP_10 Germline APC c.3810T>A p.Cys1270* Yes 
LS_EBL1 LS LS_1 Germline MSH6 c.3744_3773del p.His1248_Ser1257del Yes 
LS_EBL3 LS LS_2 Germline MSH2 c.687del p.Ala230Leufs*16 Yes 
LS_EBL5 LS LS_3 
Germline PMS2 del exon 14 p.? No 
Somatic MLH1 c.342_343del p.(Ile115Tyrfs*6)   
LS_EBL7 LS LS_4 Germline MSH2 c.1034G>A p.Trp345* Yes 
LS_EBL9 LS LS_5 
Germline MSH2 c.1661+1G>A p.? No 
Somatic MSH6 c.1340T>C p.(Leu447Pro)   
Somatic MSH6 c.3410T>C p.(Met1137Thr)   
LS_EBL11 LS LS_6 Germline MSH2 del exons 1-6 p.? No 
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Somatic MSH2 c.2172G>A p.(=)   
Somatic APC c.2626C>T     
Somatic KRAS c.485A>G p.(Glu162Gly)   
Somatic CIITA c.1436C>T p.A479V   
LS_EBL13 LS LS_7 Germline MSH2 c.1216C>T p.Arg406* Yes 
LS_EBL18 LS LS_8 Germline MSH6 c.3238_3239del p.Leu1080Valfs*12 No 
LS_EBL26 LS LS_9 
Germline MSH6 c.3860_3861insATTA p.Y1287* Yes 
Somatic MSH2 c.2646_2647del p.(Lys882Asnfs*16)   
Somatic APC c.4348C>T p.(Arg1450*)   
LS_EBL20 LS LS_10 
Germline MSH6 c.2645_2653del p.Phe882* Yes 
Somatic APC c.4234G>T p.   
Somatic APC LOH 5q     
LS_EBL23 LS LS_11 Germline MSH6 c.3699_3702del p.Lys1233Asnfs*6 Yes 
LS_T3 LS LS_12 
Germline MLH1 c.1279C>T p.Gln427* Yes 
Somatic APC c.C4549T p.Q1517X   
Somatic BRAF c.1208delC p.P403fs   
Somatic CTNNB1 c.C134T p.S45F   
Somatic AXIN1 c.1922delA p.K641fs   
Somatic RFX5 c.56delC p.P19fs   
Somatic RFXAP c.297delG p.P99fs   
LS_T2 LS LS_13 
Germline MLH1 c.1918C>T p.Pro640Ser Yes 
Somatic APC c.2540dupA p.E847fs   
Somatic KRAS c.G38A p.G13D   
Somatic MLH1 c.C350T p.T117M   
Somatic MSH6 c.666_667insGATGGAGG p.D222fs   
Somatic 
MSH6 
c.668_669insGGCACAACTT
ACGTAAC 
p.N223_E224delinsKAQ
LTX 
  
LS_T1 LS LS_14 Germline MLH1 c.2059C>T p.Arg687Trp Yes 
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4.3 Discussion 
Our results show a distinct immune profile in LS polyps, independent of the DNA 
mutation rate, the emergence of neoantigens that is secondary to frameshift mutations, and the 
MMR status. Among the immune checkpoints upregulated in polyps stand LAG3, which 
constitutes a promising target for immune interception in this patient population. Therefore, 
emergence of high mutation burdens and neoantigens cannot simply be applied as a biomarker 
to guide implementation and development of immuno-prevention strategies. In addition, we 
observed that neoantigen formation correlates with a high mutational rate present in the 
subgroup of LS polyps that are hyper-mutants. The acquisition of additional MHC class I and II 
neoantigens by hypermutated LS polyps was associated with the introduction of alterations in 
DNA damage repair pathways, which could further explain how MMR-deficiency increases 
neoantigen formation leading to hypermutation in carcinomas. 
We have demonstrated that polyps that arise in LS are enriched for CD4-positive T-
cells, which are responsible for the upregulation of the immune checkpoints PD-L1 and LAG-3. 
This is consistent with recently reported transcriptomic profiles detected in normal mucosa 
samples of LS patients that harbored a CRC, which showed strong immune response 
associated to invasion of CD4-positive T-cells, expression of immune checkpoints, and 
HLA[97]. Furthermore, we found that this transcriptional program was displayed across all 
polyp types regardless of major clinico-pathological features such as histology (it was observed 
both in adenomas and hyperplastic polyps), size, location (right versus left), the presence of 
advanced features (high-grade dysplasia), and MMR status; but, most importantly, it was 
independent of the accumulation of somatic mutations. In fact, the only difference in terms of 
immune activation displayed by the 3 polyps that were found to be hyper-mutant and MMR-
deficient compared to the rest of LS polyps was the upregulation of CTLA4, which was shared 
with LS carcinomas, and FOXP3, which is consistent with development of immune tolerance 
upon progression of carcinogenesis. In fact, the results of the analysis of immune-cell infiltrates 
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from colorectal carcinomas diagnosed in participants of the Nurses’ Health Study and the 
Health Professionals Follow-up Study reported a correlation between neoantigen load and 
density of FOXP3 positive T-cell infiltrates[98]. In addition, neoantigens accumulated along with 
the acquisition of additional indels that generate new open reading frames in hyper-mutant 
polyps are more immunogenic than single nucleotide variants. Overall, these observations are 
consistent with the results from pan-TCGA analysis that indicated that indel load is more 
closely associated with overall immunogenicity and response to checkpoint inhibition[99]. 
Therefore, our results challenge the concept that immune activation in LS is a consequence of 
the excessive accumulation of somatic variation secondary to MMR deficiency, since all polyps 
analyzed presented a consistent immune profile regardless of the mutation rate or abundance 
of high-affinity binding neoantigens. This canonical concept could be the case at later stages of 
premalignancy (advanced polyps) and progression into carcinoma. However, immune 
deregulation could precede the accumulation of genomic aberrations and neoantigen formation 
in initial steps of carcinogenesis (Figure 14). Finally, this observation will advocate for the 
development of vaccine strategies to prevent the progression of carcinogenesis by priming T-
cells to antigens displayed by early lesions that will be cleared at the premalignant stage. 
Furthermore, combinations of immune checkpoint inhibitors and vaccines could be exploiting 
both components displayed by MMR-deficient premalignancy. 
 
  77 
 
Figure 14. Schematic model of the immune activation in LS carcinogenesis.  LS 
polyps display a marked immune activation profile characterized by CD4 T -cells, pro-
inflammatory, and checkpoint molecules that is independent of mutational rates, 
neoantigen formation, and MMR status at early stages of carcinogenesis. 
Progression of mutational rate and acquisition of invasive features with evolution into 
carcinomas activate additional immune pathways with eventual development of 
immune tolerance (advanced lesions) and evasion (carcinomas).  
 
Figure 5
Figure 5. Schematic model of the immune activation in LS carcinogenesis.  LS polyps display a 
marked immune activation profile characterized by CD4 T-cells, pro-inflammatory, and checkpoint 
molecules that is independent of mutational rates, neoantigen formation, and MMR status at early 
stages of carcinogenesis. Pr gression of mutational rate and acquisition of invasive features with 
evolution into carcinomas activate additional immune pathways with eventual development of immune 
tolerance (advanced lesions) and evasion (carcinomas)
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Chapter 5 CONSENSUS MOLECULAR SUBTYPE OF SPORADIC AND HEREDITARY 
PREMALIGNANT LESIONS  
5.1 Introduction 
The canonical genetic pathway of step-wise cascade of somatic mutations in tumor 
suppressor genes and oncogenes have been described extensively in colorectal 
carcinogenesis[5, 28]. At the transcriptomic level, used large-scale gene expression-based 
profiling of primary CRC tumors to identify four distinct consensus molecular subtypes (CMS) 
with distinguished biological features and prognostic subgroups[34].  
Up to 5% of all CRC cases arise in the setting of well-defined inherited syndromes, such 
as familial adenomatous polyposis (FAP) and Lynch syndrome (LS), among others. FAP 
results from germline mutations in APC, which constitutively activates WNT/β-catenin 
mediated-transcription, driving the transformation of intestinal crypts to conventional precursor 
lesions (tubular, tubulovillous or villous adenomas). FAP-related adenomas have a spectrum of 
molecular features similar to CIN-positive CRCs[3]. LS-associated CRC results from germline 
mutations in the MMR genes (MLH1, MSH2, MSH6, PMS2 and EPCAM), with conventional 
adenomas representing the majority of precursor lesions[100]. Even though MSI is present in 
only half of LS-associated polyps at diagnosis, MMR becomes universally detected in more 
advanced precursor lesions, when larger in size[101]. An alternative route of colorectal 
carcinogenesis is the serrated pathway has been shown to be an alternative colorectal 
carcinogenetic route potentially accounting for up to one third of all CRCs. 
Serrated/Hyperplastic polyposis syndrome (SPS) is characterized by numerous sessile 
serrated adenomas (SSA), predominantly located in the right side of the colon, in addition to 
hyperplastic polyps (HP)[102]. SSA carcinogenesis pathway is associated with high CpG island 
methylation phenotype (CIMPhi) and BRAFV600E mutations as the major driving mechanisms in 
both sporadic and familial cases[22] [23]. 
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Collectively, such molecular insights of sporadic and familial CRC have been crucial in 
the development of clinical standards for managing both early-stage and advanced disease. On 
the contrary, applications towards disease risk prediction and targeted prevention still remain 
limited. This is due to a relative paucity of information regarding the full spectrum of genetic, 
epigenetic, and transcriptomic changes in benign colon polyps or pre-malignant adenomas. We 
hypothesize that filling this knowledge gap, particularly at the transcriptomic level, may lead to 
new approaches for CRC disease prevention not only in the general population, but also 
among high-risk groups such as those with familial CRC. Therefore, to more broadly 
understand the transcriptomic landscape of premalignant polyps, we have applied CMS 
classification on several cohorts of sporadic and familial adenomas with gene expression data. 
We hypothesize that: (i) most FAP-related and sporadic conventional adenomatous polyps 
(AP) have a CMS2-like (epithelial canonical) phenotype; (ii) LS polyps display a CMS1-like 
(MSI-Immune) phenotype; (iii) SSA and HP are enriched for both CMS1-like and CMS4-like 
(mesenchymal) phenotypes. 
5.2 Results 
5.2.1 Consensus molecular subtyping of a large cohort of polyps revealed CMS2 and 
CMS1 as major subtypes in premalignancy  
We first analyzed the distribution of CMS groups across polyps from different clinical 
contexts (sporadic versus hereditary syndrome) and pathologic subtype (AP, HP, and SSA). 
Overall, the majority of sporadic polyps (n=311) were classified as either CMS2 (69.5%) or 
CMS1 (21.9%), while CMS3 (5.1%) and CMS4 (1.6%) classifications were less abundant. 
Furthermore, within sporadic polyps, the majority of AP (80%) were classified as CMS2, 
whereas the majority of HP (57.1%) and SSA (76.5%) were classified as CMS1 (Figure 15A). 
Similarly, hereditary polyps (n=78) were mostly distributed between CMS2 (52.6%) and 
CMS1 (38.5%). CMS3 (2.6%) and CMS4 (6.4%) again accounted for a small percentage of 
total hereditary polyps (Figure 15B). AP from a hereditary background were predominantly 
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(86.7%) CMS2. Surprisingly, the majority (86.7%) of AP from LS patients were also classified 
as CMS2, which is in contrast to our a priori assumption. HP (71.4%) and SSA (96.2%) from a 
hereditary background were mostly classified as CMS1. Overall, these results suggest that the 
CMS2 (canonical) and CMS1 (MSI-Immune) molecular subtypes play dominant roles in early 
conventional adenomas and serrated polyps, respectively. 
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Figure 15. Circos plots presenting the distributions of consensus molecular subtype 
(CMS) groups in sporadic (A) and hereditary polyps (B). 
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5.2.2 Pathway enrichment analysis of CMS showed immune activation and classical 
WNT and MYC targets as dominant signatures in premalignancy 
We performed GSEA using previously described biological pathways and expression 
signatures pertinent to CRC carcinogenesis[34].  CMS1-like polyps were characterized by 
significant enrichment of genes involved in immune and stromal infiltration as well as pathways 
implicated in immune cytotoxicity. They also showed strong activation in JAK-STAT and MAPK 
signaling (Figure 16A-C). CMS2-like polyps displayed strong enrichment for WNT and MYC 
targets, which are classical carcinogenesis pathways in CRC (Figure 16A-C). For the small 
number polyps classified as CMS3, we did not observe significant enrichment for glutamine 
and fatty acid pathways, thus making their activation a molecular feature that arise in advanced 
adenoma or carcinoma (Figure 16A-C). Lastly, although the number of CMS4 polyps was 
small, they showed significant enrichment of mesenchymal and stromal signatures along with 
TGFβ activation (Figure 16A-C). Taken together, these analyses confirm that immune 
activation and classical carcinogenesis pathways were the main transcriptomic events in 
colorectal premalignancy. 
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Figure 16. Aggregated gene set enrichment analysis of the different consensus 
molecular subtype (CMS) groups showing signatures of interest in colorectal 
carcinogenesis (A), immune signatures (B) and canonical pathways (C). 
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5.2.3 Associations of CMS with polyp location and KRAS and BRAF mutations 
We next explored CMS distributions across various clinical-pathologic and molecular 
features. We found that CMS1 and CMS2 polyps have similar proportions in both males and 
females (Figure 17A). No statistically significant association was found between the presence 
of high-grade dysplasia/carcinoma in situ and CMS classification (Figure 17B). Interestingly, 
CMS1 polyps were more frequently presented in right colon in both sporadic (P < 0.01) and 
hereditary (P < 0.0001) cohorts. On the contrary, CMS2 polyps are more frequently presented 
in the left colon in both sporadic (P < 0.005) and hereditary (P < 0.005) cases (Figure 17C). 
These results suggest that CMS1 carcinomas may be largely derived from HP and SSA that 
are often found in the right colon. Next, we investigated mutations associated with CMS groups 
and found that BRAFV600E was more frequently present in CMS1 polyps (P < 0.0001). 
Furthermore, KRAS codon 12 and 13 mutations showed a trend to occur occurred less 
frequently among CMS1 polyps compared to CMS2 polyps (P < 0.05) did not reach statistical 
significance. Due to the small number of CMS3 polyps in our sample, we did not observe 
significant over-representation of KRAS. 
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Figure 17. Clinical, pathological and molecular associations of consensus molecular 
subtype (CMS) groups; A. Distribution by gender; B. Presence of large-grade dysplasia or 
carcinoma in situ for the subset of APs; C. polyp location; D. BRAF mutation status; E. KRAS 
mutation status. (*P<0.01, **P<0.001) 
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5.3 Discussion 
In the United States, the overall incidence of CRC has steadily decreased over the past 
decade[1] owing to increased utilization of screening colonoscopies. Yet, CRC still remains the 
third most common newly diagnosed malignancy in both men and women. Furthermore, 
despite its decreased overall incidence, an alarming trend towards younger age-of-onset (< 55 
years old) has also emerged[103]. These observations highlight an important challenge to 
better understand the molecular diversity of colonic polyps and to develop targeted approaches 
for disease prevention. Towards this end, we performed a large-scale transcriptomic analysis of 
both sporadic and familial colon polyps by applying the CMS framework.  
Taken together, our results allow the proposal of a new model for pathway activation 
driving premalignancy (Figure 18). First, we found that FAP, LS and sporadic conventional 
adenomas display an epithelial canonical CMS2 phenotype with strong WNT and MYC 
downstream targets enrichment. Secondly, we found that HP and SSA were both enriched for 
MSI-Immune CMS1 phenotype. While they displayed strong enrichment of immune and JAK-
STAT activation, they also showed enrichment in TGFβ activation and stromal signature.  Our 
results are consistent with previous studies showing that TGFβ activation play an important role 
in colorectal carcinogenesis. Using human organoid cultures and genome editing technology, 
Fessler et al investigators have shown that the genetic background of premalignant lesions 
dictates the dominating response to TGFβ, changing it from a largely apoptotic response in 
WNT pathway-activated conventional tubular adenomas to a dominant epithelial-mesenchymal 
transition response in BRAFV600E-mutated SSA[68]. Depending on the level of TGFβ on the 
microenvironment, SSA could progress to either poor-prognosis CMS4 tumors (high in TGFβ 
signaling) or the good-prognosis CMS1 tumors (low in TGFβ signaling).  
Finally, the ability to classify resected premalignant lesions into indolent versus 
aggressive molecular subtypes may have important clinical utility for colon cancer screening in 
the future. Specifically, CMS4 carcinomas have an aggressive clinical phenotype as defined by 
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a higher proportion of advanced stage at diagnosis and worse outcomes after surgery and 
adjuvant chemotherapy[34]. Extrapolating from these data, we hypothesize that CMS4-like 
premalignant lesions evolve more rapidly in the adenoma-to-carcinoma transformation process 
and may indicate the need for closer follow-up evaluation of the at-risk normal mucosa than 
would otherwise be pursued based on current surveillance guidelines. Certainly, several key 
studies are needed to explore this hypothesis and firmly establish the prognostic utility of 
premalignant CMS classification. Towards this end, analysis of longitudinal patient cohorts with 
sufficient clinical outcomes data (e.g. diagnosis of advanced adenoma or carcinoma) would be 
highly valuable. Although current CMS RF classifier has robust performance on archived tissue 
specimens, the classifier contains more than 200 genes. A new classifier requiring fewer genes 
would be ideal in clinical settings. Recently, a new CMS classifier using 38 genes derived from 
Nanostring platform shown to be suitable for FFPE samples[104]. 
We acknowledge that our study has several limitations. First, although we have 
demonstrated that CMS classification is technically feasible for premalignant tissue, it is also 
important to recognize that the classifier was derived specifically from carcinoma. As such, it is 
possible that our classification method performs sub-optimally for premalignant tissue and may 
not accurately describe its transcriptomic landscape. In future studies, the alternative approach 
would be to derive a premalignancy-specific classifier. Second, our study did not include 
comprehensive analysis of somatic single-nucleotide mutations or copy-number alterations in 
the polyp samples. These additional analyses would have allowed us to correlate various 
known CRC drivers with CMS classification of polyps. Third, we did not have information on the 
MSI status of the polyps in our study. We attempted to assess the MSI status of polyps using 
gene signatures derived from carcinoma data and hierarchical clustering but we were unable to 
observe distinct groups of samples. These limitations are primarily driven by the diminutive size 
of polyps and the requirement to prioritize tissue for gene expression analysis. Lastly, to help 
maximize the number of adenomas included in our study, we opted to classify samples 
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according to the CMS subtype with the highest posterior probability. By comparison, setting a 
minimum threshold of 0.5 posterior probability would reduce the number of analyzable samples 
significantly but would not change the overall conclusions of our study (Table 12). 
Overall, to the best of our knowledge, our study is the largest investigation of 
transcriptional drivers in colorectal premalignancy. Our results show that pathway 
dependencies of different CMS groups originally described in carcinomas are indeed 
recapitulated in adenomas, thus opening the door to more personalized development of 
targeted chemopreventive strategies for polyps, particularly in hereditary syndromes. 
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Figure 18. Model of pathway activation driving the consensus molecular subtype (CMS) 
classification in adenomatous (top) and serrated polyps (bottom). 
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Table 12 Distribution of CMS subgroups using different probability thresholds for the 
CMS RF classifier 
  RF P=0.5 RF P=0.3 
  n % n % 
CMS1 21 12.6 98 25.6 
CMS2 143 85.6 257 67.1 
CMS3 3 1.8 18 4.7 
CMS4 0 0 10 2.6 
Indeterminate 222 - 6 - 
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Chapter 6 DISCUSSION, CONLUSIONS AND FUTURE DIRECTIONS 
6.1 Discussion and Conclusions 
In the past decade, large scale sequencing studies have identified genomic and 
transcriptomic alterations of colorectal tumorigenesis[11, 34]. The results have led to 
development of novel therapeutic targets and improved disease management in late stage 
carcinomas[19, 105]. Despite the abundance of knowledge acquired in carcinoma stage, there 
have been not be sufficient systematic and large-scale efforts in characterizing colorectal 
premalignant lesions. Therefore, the purpose of this dissertation is to provide insights into the 
molecular mechanisms of early colorectal carcinogenesis using a large cohort of premalignant 
lesions and next-generation sequencing technologies. 
The “Big Bang” colorectal carcinogenesis model states that the vast majority of the 
genomic alterations are acquired during early stages of carcinogenesis and assumes that this 
massive accumulation happens after an initiating driver (APC) has occurred in a single clone 
(founder clone)[83, 84]. Subsequent acquisition of driver mutations, such as KRAS, foster 
tumor progression and generation of subclones that will acquire additional mutations. 
Therefore, the “big bang” model of colorectal carcinogenesis implies that a polyclonal 
carcinoma is derived from monoclonal origin[106]. In chapter 3, we applied bioinformatics 
approaches to determine the presence of polyclonality in premalignant lesions using whole 
exome sequencing. My results showed that 72% of the lesions are polyclonal. In addition, I did 
not detect a significant difference in the number of clones between premalignant lesions and 
stage I carcinomas, thus suggesting that polyclonality originates early in carcinogenesis and 
not at late clonal expansions. These observations suggest a model of initiation which is based 
on the expansion of an APC-driven clone that constitutes the founder progenitor of the tumor 
cell population early in carcinogenesis. The mutational profile of this founder clone contains the 
catalog of "public" mutations that are thus subsequently present in all tumor cells and include 
those cooperating with APC. The progeny of this major clone will then acquire additional 
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mutations that are the source of private low-frequency events that remain less abundant, as 
these minor subclones are marginally distributed within the geography of the tumor mass[49]. 
Overall, given the limited amount of sample material from premalignant lesions, 
bioinformatics approach such as ABSOLUTE has allowed us to uncover interesting findings 
regarding clonality through deconvoluting somatic mutations generated from whole exome 
sequencing. However, this approach also has some limitations. First, ABSOLUTE and other 
similar deconvolution methods assume that a locus does not mutate more than once in its 
evolutionary history and the mutation does not disappear or reverse, which implies a persistent 
phylogeny[107]. Thus, they assume the clusters of mutations are present at shared cellular 
frequencies and are indications of tumor populations. In simple cases, the derivation of 
mutation clusters will be correct; however, if there exist multiple subclones, then they may be 
incorrectly clustered. This error can be mitigated with high-depth targeted sequencing to more 
accurately detect the frequencies of mutations[107]. On the other hand, the “persistent” 
phylogeny assumption has been known to be violated by known phenomena such as revertant 
mutations and deletion of loci harboring mutations. Given that colorectal premalignant lesions 
are mostly diploid and harbor far fewer copy number variation events than carcinomas, this 
issue may not be as significant in premalignant lesions[49]. In addition, the cellular frequencies 
and phylogeny of mutations also rely on the tumor purity of the sample and the anatomical 
region of the biopsy [26]. Sequencing the sample at higher depth will improve the sensitivity of 
detecting low allele-frequency events in premalignant lesions because these samples have 
been shown to have around 30% dysplastic cell content[49], compared to 80% in carcinoma 
samples[108, 109]. In addition, multiple anatomical samples sequencing combined with 
Bayesian modeling can reduce the uncertainty of the mutation phylogeny by borrowing 
statistical strength across multiple datasets that is lacking in single sample data[107]. 
Furthermore, somatic copy number variations and somatic mutation often reside in the same 
region but have unknown phase or genealogical order. Therefore, tools like ABSOLUTE 
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simplify the assumption by estimating a global ratio of aneuploid and euploid cells under a 
tumor-normal-two-population assuming from somatic copy number data[108]. 
To overcome limitation of sequencing depth in WES, low purity of premalignant lesions, 
and the lack of mutational resolution in single sample data. I have performed high depth 
sequencing and sensitive digital genotyping array on driver genes in bulk tissues and crypts to 
further elucidate the model of initiation and clonality in early colorectal carcinogenesis. My 
results reveal that polyclonality is derived from independent crypts with distinct APC and KRAS 
alterations demonstrates that the presence of ITH in colorectal premalignancy is abundant and 
secondary to the presence of multiple independent lineages derived from different crypt 
progenitors. This observation contrasts with the majority of tumor evolution models that are 
based on the expansion of a single dominant clone that harbors a truncal mutation and several 
subsequent driver alterations (mainly in APC but also KRAS, TP53 and PIK3CA)[84]. These 
models ignore the degree of ITH that has been already acquired at the premalignant stage with 
multiple founder clones competing to get selected over the others, thus making the ITH 
acquired at the carcinoma stage just one snapshot of the entire tumor evolution[110]. Certainly, 
my observations are complementary to other tumor evolution models and precede them[84]. I 
speculate that polyclonality in premalignancy depends on crypt interactions by mechanisms 
involving crypt fission which leads to the recruitment of different independent lineages, and may 
not contribute further to progression but rather engulf the dominant clone[111].  
In chapter 4, I have shown that LS premalignant lesions display an activated immune 
profile of CD4+ T cells enrichment and up-regulation of proinflammatory and checkpoint 
molecules. This profile is consistent with a recent report demonstrating that mucosa from LS 
patients with carcinoma display an activated immune profile of CD4+ T cells infiltration, HLA 
and checkpoint expression[97]. Interestingly, the observed immune profile is displayed across 
lesions regardless of histology, size, MMR status, as well as mutational and neoantigen rate. 
Comparison of immune activation profile between non-hypermutated and hypermutated LS 
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polyps only demonstrated differential upregulation of CTLA4 (checkpoint), and FOXP3 (Treg), 
which is consistent with the development of immune tolerance upon CRC progression. 
Specifically, the density of FOXP3+ T cells infiltrates have been reported to be correlated with 
neoantigen load in CRC[98]. 
In addition, neoantigens accumulated along with the acquisition of additional indels that 
generate new open reading frames in hyper-mutant polyps are more immunogenic than single 
nucleotide variants. Overall, these observations are consistent with the results from pan-TCGA 
analysis that indicated that InDel load is more closely associated with overall immunogenicity 
and response to checkpoint inhibition[99]. Therefore, my results challenge the canonical 
concept that immune activation in LS is a consequence of acquisition of high levels of 
mutations and neoantigens secondary to MMR deficiency. This concept could be the case in 
later stages of premalignancy and carcinoma stage. However, immune deregulation could 
precede the accumulation of genomic aberrations and neoantigen formation in initial steps of 
carcinogenesis[72]. One possible explanation is the upregulation of proinflammatory cytokines 
(Interlukin 12A, IL12A) observed in LS polyps. IL12A is a T-cell stimulating factor which 
activates the production of Interferon gamma (INFG) and Tumor necrosis factor (TNF) from T 
cells. INFG plays a critical role in immunity as it is secreted by helper T cells and cytotoxic T 
cells as part of the adaptive immunity response while TNF is a cell signaling protein that is 
involved in systemic inflammation. The fact that these genes are also shown to be upregulated 
in LS polyps versus FAP polyps implies an immune response presence in the initial steps of 
carcinogenesis. However, further studies will be required to understand the mechanisms 
behind the upregulation of proinflammatory cytokines in the context of MMR-deficient 
carcinogenesis.  
An additional finding of this chapter is the presence of neoantigens enriched for 
deregulation of additional DNA repair pathways, which may stimulate additional genomic 
deregulation in alternative DNA repair and other pathways. Accumulation of mutations in target 
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genes involved in immune surveillance contribute in later stages of carcinogenesis to promote 
immune escape, and further progression such as mutations in the β2-microglobulin gene (B2M) 
that causes the loss of MHC class I antigen presentation[112]. Moreover, I have identified 
somatic mutations in genes regulating MHC class II (CIITA, RFX5, and RFXAP) that have been 
reported previously as microsatellite instability targets[17, 97, 113] in one of the LS 
hypermutant polyps and one of the LS carcinomas. In contrast, FAP polyps accumulated 
neoantigens that were enriched for the WNT pathway. This accumulation of genomic events in 
the WNT pathway led to activation of β-catenin in T cells, which has been identified as an 
important pathway related to immune evasion by Luke et al[94]. They have analyzed more than 
8000 TCGA carcinomas samples and classified them into T-cell-inflamed and T-cell-non-
inflamed samples. In the T-cell-non-inflamed sample group, they detected mutations in genes 
involved in WNT pathway, such as CTNNB1 and inactivating mutations in negative regulators 
such as Axin1, Axin2, APC1, and APC2[94, 114]. In addition, immunohistochemistry 
demonstrated that CD8-positive T cell infiltration and β-catenin levels are inversely 
correlated[114]. Given that 50% of the MSI-hypermutated carcinomas arise from MMR-
deficiency harbors APC inactivating mutations, inhibition of WNT signaling pathway can lead to 
higher T cell infiltration and produce a more favorable immune microenvironment for immune 
interception strategies.  
Collectively, my findings open the field of immunoprevention in LS to checkpoint 
inhibitors as an immune interception strategy. This class of agents have shown high level of 
clinical activity in the treatment of stage IV MMR-deficient CRC[18, 19]. My data is particularly 
compelling for the use of LAG3 and dual LAG3/PD1 inhibitors in the prevention space as 
demonstrated by the upregulation of both molecules in LS polyps. LAG3 is a molecule found on 
the cell surface that plays a role in the negative regulation of T-cells and binds MHC II 
molecules with high affinity[115]. Currently LAG3 inhibitors are being developed in several 
clinical trials (Clinicaltrials.gov number NCT01968109, NCT02061761). In the first-in-human 
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Phase I trials IMP321 showed no dose-limiting toxicity and the side effects were minimal[116, 
117].  
An additional immunoprevention strategy proposed in this chapter is the development of 
cancer prevention vaccines based on the presence of frameshift peptides in LS polyps. Cancer 
vaccines contain cancer-specific peptides injected into patients to boost the immune system 
ability to recognize and eliminate cancer cells. Cancer-specific frameshift peptides have been 
detected in MMR-deficient carcinomas using computational tools and existing genomic data 
from The Cancer Genome Atlas[118-121], and they have been shown to elicit immune 
response in carcinomas[99, 122] . Therefore, combinations of vaccine approaches and 
single/dual checkpoint blockage are logical next steps in immuno-prevention development in 
this hereditary disease. 
In chapter 5, my results show that FAP, LS and sporadic conventional adenomas 
display an epithelial canonical CMS2 phenotype with strong WNT and MYC downstream 
targets enrichment. Interestingly, MMR deficiency has been observed in only half of LS polyps 
at diagnosis[123, 124], but becomes nearly universal in advanced adenomas and 
carcinoma[123]. The majority of LS adenomas included in my study were early lesions (low 
grade), which likely explains the predominance of CMS2-associated signaling in these 
samples. Nonetheless, the data presented in chapter 5 in combination with chapter 4 immune 
profiling of LS polyps leads to a hypothesis that LS polyps transition from an epithelial 
phenotype (CMS2-like) with some degree of immune activation at early stages that does not 
become the complete MSI-Immune (CMS1-like) phenotype until further development of 
dysplasia and complete loss of MMR functioning, which occurs at advanced stages[72]. 
Additional correlative studies of MMR deficiency and the immune microenvironment in 
advanced LS lesions are warranted to explore this hypothesis using ex vivo organoid models 
and longitudinal samples. Secondly, I found that HP and SSA were both enriched for MSI-
Immune CMS1 phenotype. While they displayed strong enrichment of immune and JAK-STAT 
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activation, they also showed enrichment in TGFβ activation and stromal signature (Chang et al, 
submitted).  Our results are consistent with previous studies showing that TGFβ activation play 
an important role in colorectal carcinogenesis. Using human organoid cultures and genome 
editing technology, Fessler et al investigators have shown that the genetic background of 
premalignant lesions dictates the dominating response to TGFβ, changing it from a largely 
apoptotic response in WNT pathway-activated conventional tubular adenomas to a dominant 
epithelial-mesenchymal transition response in BRAFV600E-mutated SSA[68]. Depending on the 
level of TGFβ on the microenvironment, SSA could progress to either poor-prognosis CMS4 
tumors (high in TGFβ signaling) or the good-prognosis CMS1 tumors (low in TGFβ signaling).  
In addition, the ability to classify resected premalignant lesions into indolent versus 
aggressive molecular subtypes may have important clinical utility for colon cancer screening in 
the future. Specifically, CMS4 carcinomas have an aggressive clinical phenotype as defined by 
a higher proportion of advanced stage at diagnosis and worse outcomes after surgery and 
adjuvant chemotherapy[34]. Extrapolating from these data, I hypothesize that CMS4-like 
premalignant lesions evolve more rapidly in the adenoma-to-carcinoma transformation process 
and may indicate the need for closer follow-up evaluation of the at-risk normal mucosa than 
would otherwise be pursued based on current surveillance guidelines. Certainly, several key 
studies are needed to explore this hypothesis and firmly establish the prognostic utility of 
premalignant CMS classification. Towards this end, analysis of longitudinal patient cohorts with 
sufficient clinical outcomes data (e.g. diagnosis of advanced adenoma or carcinoma) would be 
highly valuable. Although current CMS RF classifier has robust performance on archived tissue 
specimens, the classifier contains more than 200 genes. A new classifier requiring fewer genes 
would be ideal in clinical settings.  
In conclusions, my data have shed light on the model of initiation step of 
carcinogenesis, characterization of the immune profile and its relation to mutation and 
neoantigen load in MMR-deficient carcinogenesis, and sub-classification of premalignancy in 
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association with different CRC subtypes. My findings establish a comprehensive molecular 
characterization of premalignant lesions and opens the field to novel development of 
chemoprevention strategies in colorectal premalignancy.  
6.2 Future Directions 
The presence of multiple independent clones derived from distinct crypts progenitors 
were detected by distinct APC and KRAS mutations. It is feasible that some of clones may not 
contribute further to progression but rather engulf the dominant clone which serves as the 
“founder” clone of CRC carcinogenesis. To study the clonal evolution dynamics of CRC in 
detail, I propose the use of single cell exome sequencing of adenoma with carcinoma in-situ to 
explore the lineage of major clones and inferred common ancestors and chronology of mutation 
from adenoma to carcinoma progression. We can perform sectioned biopsies on the sample 
and isolate single cell with flow cytometry or nanogrids that have almost no doublet error. 
Doublet errors can cause problem when reconstructing phylogenetic lineage[125]. We will use 
Monovar[126] for single nucleotide mutation detection and genotyping because of its ability to 
account for allelic dropout, sequencing false-positives errors, and non-uniform coverage. Then, 
we can apply SCITE[127], which uses a flexible Markov Chain Monte Carlo (MCMC) model to 
infer chronology of mutations and OncoNEM[128], which clusters cells into subclones and 
infers ancestral clones. This will provide novel insight on clonal diversity and evolution from 
adenoma to carcinoma progression. 
My study of immune profiling of premalignant lesions from patients with LS reveal 
upregulation of checkpoints molecules and immunogenic neoantigens, we propose several 
experiments and analyses to investigate the use of checkpoint inhibitors and vaccine 
development as chemoprevention strategies. Firstly, neoantigens generated from frameshift 
peptides (FSP) in microsatellite (MS) loci are more immunogenic than single nucleotide 
variants[17, 119]. The detection of FSP will require more sensitive bioinformatics tools than the 
ones used in this dissertation due to read-length limits and sequencing errors that vary across 
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MS loci[129]. MSMutect[129]improves the detection of FSP by performing realignment of reads 
in MS loci. Then, we will identify somatic events with a statistical test to account for noise, motif 
and length of repeats. Secondly, despite filtering for strong neoantigens based on expression 
levels and binding affinity to MHC, there are additional factors that will contribute to the 
recognition of neoantigens by T-cells, thus triggering an immune reponse[122]. These factors 
include the T-cell receptors (TCR) repertoire[130], density of T cells in the microenvironment of 
premalignant lesions [98], the integrity of the antigen presentation system[119], expression 
status of checkpoints, and the clonality of the neoantigens[131, 132]. Therefore, I propose a 
predictive model on immunogenicity of neoantigens followed by experimental validation. My 
plan is to collect a large cohort of LS premalignant lesions along with clinical and 
histopathological annotations and perform WES and RNAseq to identify HLA types and 
neoantigen candidates, and TCR repertoire sequencing to identify T-cell receptor sequences. 
Then, design a multi-variable linear regression model on (i) binding affinity of MHC molecule to 
mutant peptide versus wildtype peptide, (ii) mutation status on crucial genes required for 
antigen presentation machinery, such as B2M (MHC I), CIITA, RFX5 and RFXAP (MCH II), (iii) 
sequence similarity between mutant peptide and T cell recognized epitopes given in Immune 
Epitope Database and Analysis Resource (IEDB)[133], (iv) expression levels of immune 
activation genes, and (v) the clonal or subclonal status of the neoantigens based on in-silico 
tools. The response variable of the model will be measurement of antigen-specific T cells 
response performed with enzyme-linked immunosorbent spot (ELISPOT), a widely use method 
for measuring antigen-specific T cells[134]. Finally, vaccines can be developed based on 
predicted neoantigens and evaluated using in-vitro systems such as organoids derived from 
patient’s adenoma tissue and co-cultured lymphocytes[135]. 
The large-scale transcriptomic analysis of sporadic and hereditary shows that 
classification of resected premalignant lesions into CMS subtypes can offer clinical utility for 
CRC screening. Current follow-up guidelines after initial discovery of premalignancy depends 
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on histology, size, multiplicity, and family history[136], and CMS-like molecular subtype 
classification can improve risk prediction by providing important molecular features that is not 
captured by current morphological guidelines. Therefore, it will be crucial to perform a 
longitudinal study by tracking premalignant lesions or carcinomas occurrence and evaluate the 
prediction performance of molecular features. In addition, a new classification model may be 
desired as the current classifier is specifically optimized for carcinomas. I will first conduct a 
search for consistently expressed genes across the various types of polyps and carcinomas 
and retrain a random forest classifier to predict CMS-polyp subtypes in a large database of 
carcinoma samples with known CMS-carcinoma status (the original CMS classification was 
developed from 4500 carcinomas). Performance metrics will be assessed and compared with 
the original CMS-carcinoma classifiers to ensure that accuracy is not severely compromised 
with this new model. Then, I will apply the CMS-polyps categories to the polyp samples data 
and assess for gene enrichment across CMS-polyp groups. If strong associations between the 
CMS-carcinoma and -polyp categories are found, I will integrate the histopathological 
categorization of polyps into the novel framework and thereby associate carcinoma subtypes 
with their premalignant origins.  
In summary, I propose using single cell sequencing technology to study clonal evolution 
from premalignant to carcinoma stages, designing a predictive model for immunogenicity of 
neoantigens, studying the efficacy of cancer prevention vaccines and checkpoint inhibitors in 
MMR-deficient premalignancy, designing a transcriptomic classifier optimized for 
premalignancy and carcinomas and evaluating the performance of subtype classification for 
predicting premalignant lesions or carcinoma occurrence. 
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